Track market-moving stories before they get noisy

Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin.

• Medicus Pharma stock is testing key support levels. What’s behind MDCX weakness?

Melanotransferrin is a protein that in humans, is encoded by the MF12 gene. The protein is a cell-surface glycoprotein found on melanoma (a type of skin cancer) cells.

The co-development agreement grants Medicus full rights to utilize CD228V for the treatment, prevention, diagnosis, control and maintenance of all human diseases and disorders.

Financial Commitments and Billion-Dollar MilestonesTo obtain the license, Medicus paid a $12 million non-refundable upfront fee to Pfizer and must pay another $15 million on the first anniversary.

Read Next

To support initial progress, Pfizer delivered a $2 million development funding payment to Medicus, which must be applied solely toward executing the CD228V development plan.

Pfizer stands to gain development, regulatory, and sales milestone payments exceeding $1 billion if all target benchmarks across multiple indications are achieved. The pharmaceutical company is also eligible for low double-digit tiered royalties on annual net sales of CD228V products throughout the royalty term.

Operational Roles and Licensing TermsAlthough Pfizer maintains patent ownership and participates in co-development oversight, Medicus retains sole authority and financial responsibility for manufacturing, regulatory approval, and commercialization efforts.

Pfizer holds the right to review budgets, receive progress reports, and elect to fund product development following the initiation of the first pivotal trial.

Additionally, Pfizer will receive a portion of specified proceeds in events involving sublicensing, strategic transactions, or a change of control at Medicus.

Unless terminated early, the contract remains effective on a product-by-product and country-by-country basis until the applicable royalty terms expire.

MDCX Stock Price Activity: Medicus Pharma shares were down 32.24% to 18 cents at the time of publication on Thursday, according to Benzinga Pro data.

Image via Shutterstock

Read Next

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

A month has gone by since the last earnings report for Merck (MRK - Free Report) . Shares have added about 18.2% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Merck due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Merck & Co., Inc. before we dive into how investors and analysts have reacted as of late.

Q2 Earnings & Sales Beat EstimatesMerck reported an adjusted loss of 13 cents per share for the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 26 cents. In the year-ago quarter, the company reported adjusted earnings of $2.13 per share.

Including acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities and certain other items, loss was 54 cents per share in the second quarter versus earnings of $1.76 per share in the year-ago quarter.

Adjusted as well as reported earnings included a charge of $2.31 per share recorded in the quarter related to the acquisition of Terns Pharmaceuticals, which was completed during the period.

Revenues in the second quarter increased 5% year over year on a reported basis and 4% excluding foreign exchange (Fx) to $16.61 billion. Sales beat the Zacks Consensus Estimate of $16.33 billion. Higher sales of oncology drugs, including Keytruda and contributions from new products like Winrevair, Welireg and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines.

Quarter in DetailThe Pharmaceutical segment generated revenues of $14.76 billion, up 5% year over year (4% excluding FX). Pharmaceutical segment revenues beat the Zacks Consensus Estimate of $14.28 billion.

All sales growth numbers discussed below exclude FX impact.

Oncology DrugsCombined sales of Keytruda and Keytruda Qlex increased 4% to $8.37 billion. The reported figure topped the Zacks Consensus Estimate of $8.06 billion.

Sales of Keytruda benefited from rapid uptake across earlier-stage indications and continued strong momentum in metastatic indications.

Keytruda sales in the second quarter included $463 million in sales of Keytruda Qlex, the subcutaneous formulation of Keytruda, compared to $128 million in the previous quarter as patient adoption has increased since the permanent J-code was established in April.

Merck is seeing an increase in usage of Keytruda in tumors that primarily affect women, including cervical and breast cancers, as well as Keytruda in combination with Padcev in first-line, locally advanced or metastatic urothelial cancer.

Merck said on the conference call that Keytruda’s U.S. growth will moderate as penetration peaks in several indications. The comparison will also be impacted by a $250 million wholesaler purchase benefit in the third quarter of 2025.

On the conference call, Merck’s CEO Robert Davis said that the Keytruda exclusivity transition will create a shallow decline followed by a fast return to growth.

Alliance revenues from Lynparza declined 2% to $365 million in the quarter. Lenvima alliance revenues increased 6% to $283 million, driven by higher U.S. demand, partly offset by lower net pricing.

Welireg sales surged 67% to $271 million, reflecting higher demand in the United States for certain previously treated advanced renal cell carcinoma patients and continued launch uptake across international markets, particularly Japan. Favorable wholesaler purchasing patterns in the United States also aided performance.

VaccinesIn vaccines, sales of HPV vaccines — Gardasil and Gardasil 9 — rose 3% to $1.17 billion. Higher demand in the Asia Pacific and Europe, along with favorable tender timing in Europe, supported the franchise. These gains were partly offset by lower demand and unfavorable timing of CDC purchases in the United States. Gardasil/Gardasil 9 sales missed the Zacks Consensus Estimate of $1.18 billion.

Combined sales of ProQuad, M-M-R II and Varivax declined 3% to $592 million, mainly due to lower demand in the United States.

Sales of the pneumococcal 15-valent conjugate vaccine Vaxneuvance declined 36% to $148 million due to lower demand in the United States and most international markets as well as unfavorable comparison to the prior year quarter, as public-sector activity in the United States increased sales in that period.

Capvaxive sales increased 40% to $184 million, driven by increased demand in the United States and continued launch uptake in some international markets.

Sales of the new RSV vaccine, Enflonsia, in the United States were $2 million in the second quarter of 2026 compared with $1 million in the first quarter.

Other DrugsIn the infectious disease portfolio, Bridion sales rose 8% to $497 million due to higher demand and pricing in the United States, partially offset by lower demand in most international markets due to generic competition. Bridion lost patent exclusivity in the United States in July 2026. However, Merck expects that U.S. sales will decline at a slower pace than previously expected due to lower-than-anticipated generic competition.

Prevymis sales increased 28% to $295 million, driven by higher demand in the United States and certain European markets.

Januvia/Janumet franchise sales fell 31% year over year to $429 million. Sales of the drug declined due to lower demand and net pricing in the United States due to competition, as well as lower demand in China and most other international markets amid ongoing generic competition.

Winrevair sales jumped 75% to $588 million, reflecting continued strong demand in the United States and early launch momentum across international markets, particularly Japan and Europe.

Ohtuvayre, added from the October 2025 acquisition of Verona Pharma, contributed $204 million in sales in the second quarter compared with $131 million in the previous quarter. Revenues in the second quarter benefitted from continued prescription demand as well as favorable timing of specialty pharmacy purchases. However, third-quarter revenues will be hurt by the unwinding of specialty pharmacy purchases. Merck is investing in salesforce expansion and patient support to drive accelerated growth in 2027.

Regarding its newly launched HIV pill, Idvynso, Merck said it is seeing encouraging early progress on access and reimbursement.

Merck’s Animal Health segment generated revenues of $1.78 billion, up 8% year over year on a reported basis and 5% excluding FX. This growth was driven by higher demand for livestock as well as companion animal products. Sales from this segment marginally beat the Zacks Consensus Estimate of $1.77 billion.

Sales of livestock products rose 6% to $1.04 billion, driven by higher demand for ruminant and poultry products. Sales of companion animal products rose 5% to $734 million, driven by new product launches.

Margin DiscussionAdjusted gross margin was 81.1%, down 110 basis points year over year due to higher inventory write-offs.

Adjusted selling, general and administrative expenses rose 10% to $2.89 billion, reflecting higher administrative and promotional spending.

Adjusted research and development expenses increased almost 144% to $9.74 billion in the quarter due to a significantly higher charge of $5.7 billion related to the Terns acquisition compared to a $200 million business development charge a year ago.

Excluding these business development charges, operating expenses grew 7% in the quarter.

2026 Sales Guidance Upped, EPS Range LoweredMerck raised its sales guidance for 2026 while lowering its adjusted EPS range to include acquisition costs.

The company now expects revenues to be in the range of $66.3-$67.3 billion, compared with the previous expectation of $65.8-$67.0 billion. The new range indicates year-over-year growth of 2% to 4%.

The company now expects adjusted earnings of $2.66-$2.76 per share, down from its previous guidance of $5.04-$5.16. The revised range includes a one-time charge of $2.43 per share related to the Terns acquisition.

The 2026 guidance represents a significant decline from adjusted EPS of $8.98 in 2025 due to higher charges related to business development transactions. In 2025, Merck recorded a one-time charge of 20 cents per share related to business development transactions.

The guidance includes a positive impact from Fx of approximately 1% on sales and around 15 cents on EPS.

The adjusted gross margin is expected to be around 81%, lower than the prior expectation of approximately 82% due to higher inventory reserves.

Adjusted operating expenses are now expected to be in the range of $42.0-$42.7 billion compared with the earlier projection of $36.0 billion to $36.8 billion. The adjusted tax rate guidance was raised to 35-36% compared with the previous guidance of 23.5-24.5%.

In 2026, Merck expects to buy back shares worth $3 billion.

How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended downward during the past month.

VGM ScoresCurrently, Merck has a average Growth Score of C, a grade with the same score on the momentum front. Following the exact same course, the stock has a score of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Merck has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerMerck is part of the Zacks Large Cap Pharmaceuticals industry. Over the past month, Novartis (NVS - Free Report) , a stock from the same industry, has gained 5.2%. The company reported its results for the quarter ended June 2026 more than a month ago.

Novartis reported revenues of $14.41 billion in the last reported quarter, representing a year-over-year change of +2.5%. EPS of $2.41 for the same period compares with $2.42 a year ago.

For the current quarter, Novartis is expected to post earnings of $2.24 per share, indicating a change of -0.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.7% over the last 30 days.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Novartis. Also, the stock has a VGM Score of D.

A month has gone by since the last earnings report for Caterpillar (CAT - Free Report) . Shares have lost about 9.1% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Caterpillar due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Caterpillar Inc. before we dive into how investors and analysts have reacted as of late.

Caterpillar Q2 Earnings Beat Estimates on Higher Volume and PricingCaterpillar reported adjusted earnings of $8.17 per share for the second quarter of 2026, up 73% year over year. The figure surpassed the Zacks Consensus Estimate of $6.25 by 30.72%. Higher sales volume and favorable price realization supported the performance.

Including one-time items, Caterpillar’s earnings per share were $7.77 compared with $4.62 in the year-ago quarter.

Caterpillar's Q2 Revenues Powered by Volume, Reports Record BacklogSales and revenues increased 24% to $20.5 billion and topped the consensus estimate of $19.3 billion by 6.37%. The quarter marked Caterpillar’s first-ever revenue total above $20 billion. The increase primarily reflected $3.1 billion of higher sales volume and $595 million of favorable price realization. Currency movements added $199 million, while Financial Products revenues contributed another $67 million.

Higher sales of equipment to end users drove the volume increase. Sales rose across all three primary operating segments and every geographic region. Caterpillar’s order backlog surged 92% year over year to a record $72 billion.

Caterpillar's Margins Expand Sharply in Q2Cost of goods sold rose 18% to $12.781 billion. Gross profit was up 34.7% to $7.76 billion from the prior-year quarter. The gross margin expanded 300 basis points to 37.8% from the year-ago quarter.

Selling, general and administrative expenses increased 19% to $2 billion, while research and development expenses advanced 12% to $616 million. Operating profit increased 50% year over year to around $4.3 billion. The operating margin expanded to 20.9% from 17.3%, as the profit contribution from higher volume and pricing more than offset increased operating expenses.

Adjusted operating profit climbed 54% to around $4.5 billion, while the adjusted operating margin improved to 21.9% from 17.6%. The quarter included $392 million of expected International Emergency Economic Powers Act (IEEPA) tariff recoveries.

Segments Deliver Higher Sales and Improved ProfitsTotal Machinery, Power & Energy (MP&E) sales rose 24.9% year over year to around $19.6 billion. Operating profit was around $4.2 billion, up 51% year over year.

Construction Industries delivered the strongest segment sales growth. Revenues increased 35% to $8.3 billion, driven by $1.7 billion of higher volume and $309 million of favorable price realization. Segment profit advanced 57% to $1.9 billion, due to the higher sales volume. Margin widened to 23.3% from 20.1% in the prior-year quarter.

Resource Industries sales rose 20% to $4.6 billion, mainly reflecting higher equipment sales to end users.  Segment profit increased 23% to $693 million. Margin edged up to 14.9% from 14.5%, as higher volume offset $158 million of unfavorable manufacturing costs.

Power & Energy sales increased 17% year over year to $8.2 billion. The improvement reflected $736 million of higher volume, $212 million of favorable pricing and a $200 million increase in intersegment sales. The segment reported sales growth in Power Generation (29%), followed by 9% growth in Industrial and Oil and Gas sectors. Segment profit rose 30% to $2 billion and segment margin expanded 250 basis points to 24.6%. Volume and pricing benefits outweighed $149 million of unfavorable manufacturing costs, mainly related to higher period manufacturing expenses.

Financial Products revenues advanced 10% to $1.1 billion on higher average earning assets. Segment profit increased 32% to $328 million, aided by earning-asset growth and improved Insurance Services results, partly offset by a higher provision for credit losses.

Caterpillar's Cash Flow and Outlook StrengthenMachinery, Power & Energy operating cash flow reached $5.7 billion, up 94% year over year. Free cash flow more than doubled to $5.1 billion. CAT returned $2.2 billion to shareholders through $1.5 billion of share repurchases and $700 million of dividends. Caterpillar ended the quarter with $6.7 billion in cash and equivalents.

Caterpillar's Expectations for Q3 & 2026Looking to third-quarter 2026, management expects strong growth in sales and revenues compared with the year-ago period. Tariff costs are expected to be in line with the year-ago quarter. CAT anticipates the adjusted operating margin to be higher year over year in the third quarter. For context, the adjusted operating margin was 17.5% in the third quarter of 2025.

For 2026, management expects sales and revenues to grow in the mid-to-high teens. Adjusted operating margin is projected near the bottom of its target range, excluding tariff recoveries. MP&E free cash flow is expected in the top half of the company’s target range. The company forecasts tariff costs of around $2.2 billion, excluding tariff recoveries.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 5.33% due to these changes.

VGM ScoresAt this time, Caterpillar has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Caterpillar has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Key Takeaways MetLife's adjusted earnings rose 15% and total premium increased 5.8% in Q2 2026.MET is using AI, asset management and its New Frontier strategy to support scalable growth.MetLife's strong liquidity supports shareholder returns through share repurchases and dividend payouts. MetLife, Inc. (MET - Free Report) benefits from its diversified product portfolio, strong corporate relationships and global footprint, which support steady business volumes and premium growth. Its cost-cutting efforts, cash generation ability, strategic acquisitions and partnerships further support growth. Over the past year, shares of MET have grown 17.9%, outperforming the industry’s 4.6% rise.

MetLife — with a market capitalization of $62 billion — primarily provides protection and investment products to a range of individual and institutional customers. Beyond offering individual annuities, insurance and investment products, the company also delivers group insurance, as well as retirement and savings products and services. Its forward P/E of 9.30X is higher than the industry average of 9.17X.

Courtesy of solid prospects, MET currently carries a Zacks Rank #3 (Hold) and a Value Score of A.

MET’s Growth DriversMetLife continues to benefit from broad-based growth across its businesses, supported by stronger sales, favorable underwriting trends and improving operating momentum. Adjusted earnings rose 15% year over year to $1.6 billion in the second quarter of 2026, while total premium increased 5.8%.

Group Benefits remains an important contributor, supported by customer additions, broader product adoption and digital capabilities. MET continues to see strong opportunities in retirement and international markets. RIS-adjusted PFOs, excluding pension risk transfers, increased 19%, led by U.K. longevity reinsurance and structured settlement sales, while newer solutions such as U.K. FundedRe are broadening the platform. In Asia, sales climbed 17% on a constant-currency basis, helped by product launches and equity market tailwinds in Korea, while Latin America and EMEA sales rose 9% and 15%, respectively, creating additional room for expansion.

MET is also using technology and asset management to support scalable growth. AI-driven productivity gains are helping the company manage expenses while improving customer service and creating opportunities to apply data across policies, claims and service interactions. Meanwhile, MetLife Investment Management is expanding its role as the company grows its asset base and captures benefits from the integration of PineBridge.

MET’s New Frontier strategy combines capital-light and capital-driven businesses, leveraging its retirement origination, investment and risk-management capabilities to pursue growth while creating additional assets for its investment management platform. This model supports earnings diversification and more efficient capital deployment. The company also has flexibility to pursue additional growth through reinsurance, third-party capital and targeted acquisitions. Reinsurance can help MetLife originate more retirement business while creating additional assets for its investment management platform. The company is also evaluating selective opportunities in asset management and Group Benefits that can add complementary capabilities without requiring transformational deals.

MetLife’s robust liquidity position, evidenced by $19.3 billion in cash and cash equivalents as of June 30, 2026, far exceeds its short-term debt of $460 million. This financial strength supports shareholder returns through share repurchases and dividend payouts. The company bought back common shares worth $700 million in the second quarter of 2026. It pursued additional repurchases of roughly $225 million in July 2026. Its dividend yield of 2.5% remains higher than the industry’s average of 2.4%.

Where Do Estimates for MET Stand?The Zacks Consensus Estimate for MetLife’s 2026 earnings is pegged at $9.76 per share, indicating a 10.5% year-over-year rise, which has been revised upward over the past seven days. Furthermore, the consensus mark for revenues is pegged at $78.7 billion for 2026. It beat earnings estimates in each of the past four quarters, with an average surprise of 5.7%.

MET Stock: Risks to WatchHowever, there are some factors that investors should keep a careful eye on.

MET’s variable investment income has been volatile in recent years and remained below target at $1.5 billion in 2025. The first quarter of 2026 produced $518 million of pre-tax variable investment income, but the second quarter fell to $231 million due to lower private equity returns, and real estate and other fund returns.

The company’s return on invested capital (ROIC) is 1.9%, below the industry average of 2%. This indicates relatively weaker capital efficiency and modest returns on its investments.

Better-Ranked PlayersSome better-ranked stocks in the insurance space are Hippo Holdings Inc. (HIPO - Free Report) , Slide Insurance Holdings, Inc. (SLDE - Free Report) and The Hanover Insurance Group, Inc. (THG - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Hippo Holdings’ current-year earnings is pinned at $2.46 per share and has witnessed two upward revisions in the past 60 days against no movement in the opposite direction. HIPO beat earnings estimates in each of the trailing four quarters, with the average surprise being 521.8%. The consensus estimate for current-year revenues is pegged at $581.9 million, implying 24.2% year-over-year growth.

The Zacks Consensus Estimate for Slide Insurance Holdings’ current-year earnings is pinned at $3.79 per share and has witnessed two upward revisions in the past 60 days against one movement in the opposite direction. SLDE beat earnings estimates in each of the trailing four quarters, with the average surprise being 36.9%. The consensus estimate for current-year revenues is pegged at $1.5 billion, implying 29.5% year-over-year growth.

The Zacks Consensus Estimate for Hanover Insurance Group’s current-year earnings is pinned at $20.17 per share and has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. THG beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.3%. The consensus estimate for current-year revenues is pegged at $7 billion, implying 4.6% year-over-year growth.

A month has gone by since the last earnings report for W.W. Grainger (GWW - Free Report) . Shares have lost about 0% in that time frame, outperforming the S&P 500.

Will the recent trend continue leading up to its next earnings release, or is W.W. Grainger due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for W.W. Grainger, Inc. before we dive into how investors and analysts have reacted as of late.

Grainger Beats Q2 Earnings Estimates on Margin Gains, Raises OutlookGrainger reported second-quarter 2026 earnings of $12.01 per share, up 20.5% year over year. The figure beat the Zacks Consensus Estimate of $11.28 by 6.47%, aided by strong sales growth, and wider gross and operating margins.

Quarterly sales increased 10.3% year over year to $5.02 billion and surpassed the consensus estimate of $4.95 billion by 1.35%. Daily sales advanced 10.3%, reflecting solid momentum across both operating segments. We predicted daily sales to increase 8.5%. 

On a daily, organic constant currency basis, sales increased 13.7%. The comparison adjusts for foreign currency movements and the company’s exit from the U.K. market, including the divested Cromwell business and closed Zoro U.K. operations.

Grainger’s Q2 Segmental PerformanceThe High-Touch Solutions N.A. segment’s daily sales rose 11.9% year over year in the second quarter of 2026, reflecting strong volume growth and a healthy contribution from pricing. The Endless Assortment segment’s daily sales grew 13.5% year over year in the quarter, supported by strong performances at MonotaRO and Zoro.

GWW Expands Profitability in Q2Gross profit increased 13% year over year to $1.98 billion. The gross margin expanded 100 basis points to 39.5%, supported by improvement in both segments and benefits related to the U.K. market exit.

The quarter included $43 million in refunds on IEEPA tariffs for products directly imported by Grainger. These refunds reduced the cost of goods sold and provided a roughly 90-basis-point benefit to the gross margin. The cost of sales came in at $3.04 billion, 8.5% year over year.

Selling, general and administrative expenses rose 9.3% to $1.18 billion. Grainger’s operating earnings in the quarter increased 19% year over year to $807 million. The operating margin came in at 16.1% compared with 14.9% in the prior-year quarter.

Grainger Generates Solid Cash FlowThe company had cash and cash equivalents of $589 million as of June 30, 2026, compared with $585 million at the end of 2025. The cash flow from operating activities was $1.18 billion in the first six months of 2026 compared with $1.02 billion in the prior-year period.

Long-term debt was $2.41 billion as of June 30, 2026, compared with $2.36 billion as of Dec. 31, 2025. Grainger returned $341 million to shareholders through dividends and share repurchases during the quarter.

GWW Raises Its 2026 OutlookGrainger raised its 2026 net sales guidance to $19.4-$19.7 billion from $19.2-$19.6 billion. The company expects reported sales growth of 8.4-10% from the prior mentioned 6.7-9.1%.  

The adjusted earnings guidance was increased to $45.50-$47.25 per share from $44.25-$46.25. Grainger also raised its operating margin outlook to 15.8-16.2% and the gross margin forecast to 39.3-39.6%. The updated outlook reflects strong first-half execution, improving MRO market demand and better top-line leverage.

How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.

VGM ScoresAt this time, W.W. Grainger has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock has a grade of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, W.W. Grainger has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

A month has gone by since the last earnings report for Duke Energy (DUK - Free Report) . Shares have lost about 2.3% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Duke Energy due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

Duke Energy Q2 Earnings Beat Estimates, Revenues Increase Y/Y

Duke Energy Corporation's second-quarter 2026 earnings of $1.43 per share surpassed the Zacks Consensus Estimate of $1.29 by 10.9%. The bottom line increased 14.4% from $1.25 reported in the year-ago quarter.

DUK’s RevenuesTotal operating revenues were $7.59 billion, which missed the Zacks Consensus Estimate of $7.72 billion by 1.6%. The top line increased 1% from $7.51 billion in the year-ago period.

Highlights of DUK’s Q2 ResultsOperating expenses amounted to $5.55 billion, down 2.4% year over year. The decrease was primarily due to lower cost of natural gas, operation, maintenance and other and lower property and other taxes.

The operating income totaled $2.05 billion compared with $1.83 billion in the year-ago quarter.

Interest expenses rose to $957 million from $897 million in the second quarter of 2025.

The average number of customers in its Electric Utilities and Infrastructure increased 1.4% year over year.

Total electric sales volume for the reported quarter went up 0.4% year over year to 64,442 gigawatt-hours.

DUK’s Segmental HighlightsElectric Utilities & Infrastructure: This segment’s adjusted earnings totaled $1.3 billion, up from $1.2 billion in the second quarter of 2025. This was primarily driven by the recovery of investments in infrastructure needed to reliably serve customers across its growing jurisdictions, partially offset by higher depreciation associated with an expanding asset base and increased interest expense.

Gas Utilities & Infrastructure: Adjusted earnings from this segment amounted to $10 million compared with $6 million in the second quarter of 2025. This was primarily driven by recovery of infrastructure investments to reliably serve customers in its growing jurisdictions, offset by lower earnings from the sale of Piedmont's Tennessee business.

Other: The segment includes corporate interest expenses not allocated to other business units, resulting from Duke Energy’s captive insurance company and other investments. On an adjusted basis, this segment incurred a loss of $204 million compared with a loss of $228 million in the second quarter of 2025. Higher quarterly results were primarily driven by higher returns on investments and lower interest expense.

Financial Condition of DUKAs of June 30, 2026, Duke Energy had cash & cash equivalents of $673 million compared with $245 million as of Dec. 31, 2025.

As of June 30, 2026, the long-term debt was $82.24 billion compared with $80.11 billion as of Dec. 31, 2025.

During the first six months of 2026, the company generated net cash from operating activities of $4.27 billion compared with $5.04 billion a year ago.

2026 Guidance by DUKDuke Energy expects to generate 2026 adjusted EPS in the range of $6.55-$6.80. The Zacks Consensus Estimate for 2026 earnings is pegged at $6.72, which is higher than the midpoint of the company’s projected range.

The company expects long-term adjusted EPS growth of 5-7% through 2030.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in fresh estimates.

VGM ScoresCurrently, Duke Energy has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Following the exact same course, the stock has a score of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Duke Energy has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

It has been about a month since the last earnings report for DaVita HealthCare (DVA - Free Report) . Shares have lost about 4.9% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is DaVita HealthCare due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.

DaVita Q2 Earnings Beat Estimates, Margins DownDaVita Inc. (DVA - Free Report) delivered adjusted earnings per share from continuing operations of $4.02 in the second quarter of 2026, up 36.3% year over year. The figure surpassed the Zacks Consensus Estimate by 0.3%.

GAAP earnings per share from continuing operations for the quarter was also $4.02, reflecting an uptick of 55.8% year over year.

DaVita’s Revenues in DetailRevenues of $3.55 billion in the second quarter increased 5.2% year over year. The figure topped the Zacks Consensus Estimate by 0.6%.

RPT in the second quarter of 2026 was $415.9, up 2.8% year over year, but down 0.4% sequentially. Per management, the sequential decline reflected a lower commercial mix from declining Affordable Care Act enrollment and lower sequential revenue contribution from phosphate binders.

DVA’s Segment DetailsDaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues.

The dialysis patient service revenues were $3.37 billion, up 4.9% year over year.

Other revenues were $187.7 million, up 8.7% from the year-ago quarter’s figure.

Per management, the total U.S. dialysis treatments for the second quarter were 7,226,600 or 92,649 per day, on average. This represents a per-day increase of 1.09% on a sequential basis. Normalized non-acquired treatment increased 0.3% year over year in the second quarter of 2026.

As of June 30, 2026, DaVita provided dialysis services to around 298,500 patients at 3,266 outpatient dialysis centers, of which 2,671 were U.S. centers while 595 were located across 14 other countries.

As of June 30, 2026, DVA had approximately 64,900 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.8 billion in annualized medical spend. The company also had an additional 5,700 patients in other integrated care arrangements.

DaVita’s Margin DetailsIn the quarter under review, DaVita’s gross profit increased 3.9% year over year to $1.16 billion. However, the gross margin contracted 38 basis points (bps) to 32.7%.

General & administrative expenses climbed 2.6% year over year to $423.5 million.

Adjusted operating profit totaled $738.6 million, reflecting a 4.7% increase from the prior-year quarter’s level. Adjusted operating margin in the second quarter contracted 8 bps to 20.8%.

DVA’s Financial PositionDaVita exited second-quarter 2026 with cash and cash equivalents and short-term investments of $688.9 million compared with $666.5 million at the end of the first quarter of 2026. Total debt (including the current portion) at the end of second-quarter 2026 was $10.78 billion compared with $10.63 billion at the end of the first quarter of 2026.

Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $810.9 million compared with $504.2 million a year ago.
During the three months ended June 30, 2026, DVA repurchased 2.2 million shares for $348 million. Subsequent to June 30, through Aug. 4, 2026, the company has repurchased 0.2 million shares of its common stock for $37 million.

DaVita’s GuidanceDaVita has revised its outlook for 2026.

For 2026, DVA continues to expect RPT to reflect growth of 1%-2%, while treatment volume is expected to be near the top end of the company’s previous guidance range of 25 to 50 bps.

Adjusted earnings per share from continuing operations for the full year remains expected in the range of $14.10-$15.20. The Zacks Consensus Estimate is currently pegged at $15.07.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.

The consensus estimate has shifted -12.69% due to these changes.

VGM ScoresCurrently, DaVita HealthCare has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a score of A on the value side, putting it in the top quintile for value investors.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, DaVita HealthCare has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerDaVita HealthCare is part of the Zacks Medical - Outpatient and Home Healthcare industry. Over the past month, Quest Diagnostics (DGX - Free Report) , a stock from the same industry, has gained 2.1%. The company reported its results for the quarter ended June 2026 more than a month ago.

Quest Diagnostics reported revenues of $3.04 billion in the last reported quarter, representing a year-over-year change of +10.2%. EPS of $3.12 for the same period compares with $2.62 a year ago.

Quest Diagnostics is expected to post earnings of $2.85 per share for the current quarter, representing a year-over-year change of +9.6%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.1%.

Quest Diagnostics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.

It has been about a month since the last earnings report for Wayfair (W - Free Report) . Shares have lost about 12.1% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Wayfair due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Wayfair Inc. before we dive into how investors and analysts have reacted as of late.

Wayfair Q2 Earnings Beat Estimates on U.S. Demand, Market Share GainsWayfair reported second-quarter 2026 earnings of 95 cents per share, which beat the Zacks Consensus Estimate of 94 cents. Net revenues for the second quarter of 2026 rose 7.5% year over year to $3.52 billion, surpassing the Zacks Consensus Estimate of $3.47 billion by 1.41%.

The outperformance was driven by accelerating U.S. demand, sustained market share gains and outsized growth from the company's specialty and luxury brands, including Perigold.

Last Twelve Months (LTM) net revenues per active customer increased 4.2% year over year to $596 as of June 30, 2026. The active customer base rose 3.3% year over year to 21.7 million.

Wayfair’s Q2 in DetailsNet revenues in the United States (88.8% of total net revenues) increased 8.7% year over year to $3.13 billion, the strongest growth the segment has posted in the post-pandemic period. International net revenues (11.2% of total net revenues) declined 1.3% year over year to $394 million. On a constant currency basis, international revenues declined 2% year over year.

Orders per customer (LTM orders delivered divided by active customers) were 1.89 for the quarter, up from 1.86 in the second quarter of 2025. The average order value expanded from $328 to $332 year over year.

Total orders delivered in the second quarter were 10.6 million, up 6% year over year. Repeat customers placed 8.5 million orders (80.2% of total orders delivered), representing an increase of 4.9% year over year compared with 80.7% of total orders in the second quarter of 2025. Mobile orders accounted for 64.1% of total orders delivered, up from 62.9% in the second quarter of 2025.

Operating Results of WayfairWayfair's second-quarter gross profit was $1.05 billion, representing a gross margin of 30%, which contracted 10 basis points year over year. Non-GAAP Contribution Profit was $539 million, or 15.3% of net revenues, representing a contribution margin improvement of 10 basis points year over year. Adjusted EBITDA was $242 million in the reported quarter, up 18% year over year, representing an adjusted EBITDA margin of 6.9%, which expanded 60 basis points year over year and marked the company's best margin performance since 2021.

Customer service and merchant fees represented 3.6% of net revenues. Advertising expenses represented 11.1% of net revenues, an improvement of roughly 30 basis points from the second quarter of 2025. Selling, operations, technology and general and administrative (SOT G&A) expenses were $361 million for the quarter, delivering 100 basis points of leverage against the prior-year period.

Wayfair reported a GAAP net loss of $1 million for the second quarter against GAAP net income of $15 million in the second quarter of 2025. GAAP loss per share was 1 cent versus earnings of 11 cents a year earlier. Second-quarter results included a $59 million loss on debt extinguishment tied to the repurchase of 2028 convertible notes.

Balance Sheet & Cash Flow of WayfairAs of June 30, 2026, cash and cash equivalents were $1.07 billion, and short-term investments were $78 million, bringing the combined total to $1.14 billion compared with $1.06 billion as of March 31, 2026. Total liquidity reached $1.6 billion, including availability under the revolving credit facility, up from $1.5 billion as of March 31, 2026.

Long-term debt as of June 30, 2026, was $2.8 billion compared with $2.93 billion as of March 31, 2026, reflecting the redemption of the remaining 2028 convertible notes, funded in part through the issuance of a $400 million high-yield note.

Net cash provided by operating activities was $360 million in the second quarter, up from $273 million in the second quarter of 2025. Non-GAAP free cash flow was $301 million, up more than 30% year over year and the strongest quarterly figure since the second quarter of 2020. Capital expenditures totaled $59 million for the quarter.

Q3 2026 GuidanceFor the third quarter of 2026, Wayfair expects revenues to grow in the high single digits year over year.

The company expects gross margin in the range of 29.5% to 30.5% of net revenues, with results likely landing toward the lower end as investment in the customer experience, including the loyalty program, continues.

Customer service and merchant fees are expected to be just below 4% of net revenues, while advertising is expected in the 10.5% to 11.5% range, also toward the low end. Together, this should yield a contribution margin in line with or slightly better than the second quarter. SOT G&A is expected to hold in the $360 million to $370 million range.

Adjusted EBITDA margin is guided in the 6% to 7% range for the third quarter.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 71.26% due to these changes.

VGM ScoresCurrently, Wayfair has a strong Growth Score of A, a grade with the same score on the momentum front. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Wayfair has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry PlayerWayfair is part of the Zacks Internet - Commerce industry. Over the past month, Carvana (CVNA - Free Report) , a stock from the same industry, has gained 6.7%. The company reported its results for the quarter ended June 2026 more than a month ago.

Carvana reported revenues of $7.38 billion in the last reported quarter, representing a year-over-year change of +52.4%. EPS of $0.42 for the same period compares with $0.26 a year ago.

For the current quarter, Carvana is expected to post earnings of $0.49 per share, indicating a change of +133.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.9% over the last 30 days.

Carvana has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.

Key Takeaways AMC's Leawood Films will distribute movies without financing their production costs.AMC's Q2 adjusted EBITDA surged 70% YoY to $321.4M as attendance and per-patron spending strengthened.AMC's 69% YTD rally likely faces a test from elevated leverage and uneven full-year cash generation. AMC Entertainment Holdings, Inc. (AMC - Free Report) is attracting attention following the creation of Leawood Films, a distribution venture designed to bring more small and medium-sized movies to theaters. The initiative is expected to leverage AMC’s global exhibition network, marketing capabilities and industry relationships without requiring the company to finance film production.

The announcement builds on AMC’s record-breaking second-quarter results and historic attendance generated by The Odyssey and Spider-Man: Brand New Day. AMC shares have surged approximately 69.2% year to date, outperforming the Zacks Leisure and Recreation Services industry and the S&P 500.

AMC’s YTD Price Performance
Image Source: Zacks Investment Research

With operating momentum strengthening and Leawood Films opening another potential revenue channel, should investors chase AMC’s rally? Let’s analyze.

Leawood Films Expands AMC’s Growth StoryLeawood Films will focus primarily on distributing small and medium-sized releases that might otherwise struggle to secure theatrical backing. The venture will work only with completed films or projects whose production costs have already been fully financed by filmmakers. This structure limits AMC’s exposure to the development and production risks traditionally associated with movie studios.

AMC plans to use its ability to secure screens, market films and collaborate with other domestic and international exhibitors. The model builds on the company’s distribution experience with Taylor Swift: The Eras Tour, Renaissance: A Film by Beyoncé and Taylor Swift: The Official Release Party of a Showgirl.

The venture is intended to supplement rather than compete with content supplied by AMC’s major studio partners. It will also preserve a theatrical window of at least 45 days before premium video-on-demand availability and 90 days or more before subscription streaming. Leawood Films could help AMC utilize excess theater capacity while broadening the supply of theatrical content. Leawood Films has not selected its initial releases, and its first projects are not expected to reach theaters until sometime in 2027 or 2028.

Record Theater Momentum Strengthens AMC’s Investment CaseLeawood Films arrives as AMC’s core exhibition business shows meaningful improvement. More than 71 million guests visited AMC and ODEON theaters during the second quarter of 2026, up 13.5% year over year. Revenues increased 14.2% to approximately $1.6 billion, while adjusted EBITDA surged 70% to a company-record $321.4 million.

The adjusted EBITDA margin expanded 650 basis points to 20.1%. Approximately $200 million of incremental revenues generated $131.9 million of additional adjusted EBITDA, representing roughly 66% flow-through. Free cash flow reached $190.1 million, highlighting the operating leverage and cash-generation potential available when attendance growth combines with higher per-patron spending and cost discipline.

The momentum extended into the third quarter. From July 16 through July 26, The Odyssey generated AMC’s highest IMAX revenues through the first two weekends of any film in the company’s history. AMC operates approximately half of all IMAX screens in the United States, positioning the company to benefit from growing demand for immersive theatrical experiences.

The subsequent opening of Spider-Man: Brand New Day, together with continued demand for The Odyssey and other releases, drove AMC’s highest-revenue Wednesday-through-Sunday period in its 106-year history. More than 10.2 million guests visited AMC and ODEON locations, producing company records for admissions and food-and-beverage revenues.

AMC’s Premium Formats and Loyalty Support SpendingPremium viewing formats are strengthening AMC’s ability to monetize attendance. Premium large-format and XL auditoriums represented about 8% of AMC’s screen base but generated more than half of its ticket revenues from The Odyssey during the film’s opening weekend. AMC intends to continue expanding its IMAX, Dolby Cinema, Prime, iSense and XL footprint, which should support its premium-ticket mix and revenue per patron.

Loyalty and ancillary offerings provide additional support. AMC Stubs members represented slightly more than half of the company’s U.S. guest count in the second quarter, while the A-List subscription program exceeded 1.1 million members and accounted for approximately 20% of domestic patronage. Meanwhile, AMC expects its movie-themed merchandise business to generate more than $100 million in revenues during 2026.

AMC’s Valuation and Competitive LandscapeFrom a valuation standpoint, AMC stock appears inexpensive, trading at a forward 12-month price-to-sales ratio of 0.42X, substantially below the industry average of 2.71X. The stock also trades at a discount to Cinemark Holdings, Inc. (CNK - Free Report) and The Marcus Corporation (MCS - Free Report) , which carry respective forward sales multiples of approximately 1.12X and 1.04X.

Image Source: Zacks Investment Research

AMC faces strong competition from Cinemark and Marcus, both of which entered the second half of 2026 with solid operating momentum and stronger financial flexibility. Cinemark surpassed $1 billion in quarterly revenues for the first time and generated a record adjusted EBITDA of $294 million, a 27.1% margin and nearly $300 million in free cash flow. The company continues to see growth opportunities across premium formats, strategic pricing, concessions and loyalty, although the sustainability of its market-share gains will depend on film mix and a consistent box-office recovery. Marcus reported 16.6% growth in comparable theater admissions revenues and a nearly 37% increase in theater-adjusted EBITDA to $36.3 million. Its $44 million in free cash flow, 1.1X net leverage and hotel business provide added financial strength and earnings diversification, while premium screens at 84% of its theater locations position it to capture demand for higher-priced formats.

AMC’s competitive position is supported by its global scale, broad premium-format footprint and established loyalty base, with Leawood Films adding a new distribution opportunity. However, Cinemark’s stronger margin and free-cash-flow performance and Marcus’ lower leverage highlight areas where AMC still has room to strengthen its financial profile.

AMC’s Risk Factors and MitigationAMC’s performance remains closely tied to the timing and audience reception of theatrical releases. Film delays or weaker-than-expected box-office results could pressure attendance, ticket revenues and concession sales. Although AMC generated $190.1 million in free cash flow during the second quarter, it has not yet achieved positive free cash flow over a full 12-month period. The company estimates that the annual domestic industry box office will need to reach approximately $10.4 billion to meet that goal. AMC’s working-capital cycle typically has a negative cash impact in the first and third quarters, adding to quarterly cash-flow volatility.

The balance sheet remains another concern. AMC’s leverage has fallen below 6.5 times but remains well above its long-term target of approximately three times, while recent equity offerings have diluted existing shareholders.

ConclusionAMC’s Leawood Films initiative represents a strategically sensible extension of the company’s exhibition and marketing capabilities. Its limited production-risk structure, combined with AMC’s global screen network, could broaden theatrical content and generate incremental revenues over time. Record second-quarter results, historic blockbuster weekends and strong premium-format demand further demonstrate that the company’s operating recovery is gaining traction.

However, Leawood Films is not expected to be a near-term earnings driver. AMC also remains exposed to an unpredictable film slate, elevated leverage, potential shareholder dilution and uneven cash-flow generation. Moreover, the stock’s substantial year-to-date rally suggests that part of the operating recovery may already be reflected in its price.

Against this backdrop, existing shareholders may consider retaining AMC stock while prospective investors may prefer to wait for a better entry point. AMC currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Jim Cramer says Broadcom's AI revenue forecast is the jaw-drop number of the year, but the customer driving it is a company no retail investor can actually own, and that hidden dependency may be the only thing that matters for…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Jim Cramer walked onto CNBC’s Squawk on the Street Thursday morning with a warning that reframes the entire Broadcom AI trade. "This is now Anthropic. It’s Anthropic or bust… They need Anthropic to have a blockbuster IPO." The most important customer underwriting the biggest custom-silicon guide in semiconductor history is a company you cannot buy on any exchange.

I’ve been following Broadcom (NASDAQ:AVGO | AVGO Price Prediction) since the Avago days, and I have never seen a forward number quite like the one Hock Tan dropped after the close on Tuesday. The reaction the next morning was brutal.

Jaw-Drop Number Behind the Selloff Broadcom’s Q3 FY2026 was strong on its own. Revenue came in at $29.59 billion, up 85.5% year over year, with AI semiconductor revenue of $16.7 billion, growing 221% year over year and 54% sequentially. Non-GAAP EPS of $3.32 extended the beat streak to nine straight quarters.

Then Tan gave the number Cramer called the "jaw drop statement" of the call. Broadcom expects AI semiconductor revenue to reach approximately $115 billion in fiscal 2027, and then double again in fiscal 2028 to $230 billion. Tan added that Q3 demand "was simply hot and we’re just getting started" and that customer compute needs would "inflate even more in 2027 and 2028."

Investors sold it anyway. AVGO closed at $367.24 Wednesday and traded at $352.04 by Thursday midday, down 4%. The stock is now down 6% over the past month, even though it remains up 24% year over year.

Why Anthropic Is the Whole Story Tan named the customers behind the number. Anthropic is deploying one gigawatt of Ironwood in 2026, another five gigawatts of TPU v8i in 2027, and has line of sight to an incremental 10 gigawatts in 2028. Tan said Anthropic "is on track to become our largest XPU customer in 2027 and sustain that in 2028."

OpenAI is second on the list, with 1.3 gigawatts of Jalapeno planned for 2027 and line of sight for over 5 gigawatts in 2028. Google, Meta, and two unnamed customers round out the six. Broadcom’s own Q3 8-K filing lists "dependence on a limited number of significant customers for AI semiconductor demand" as a risk factor.

Here is the problem for a retail investor. Anthropic is private. If you want exposure to the customer that will supposedly drive Broadcom’s largest single revenue line to $230 billion in fiscal 2028, you cannot get it directly. Cramer’s point is that an Anthropic IPO becomes the clearing event that validates the entire chain.

NVIDIA Comparison Matters NVIDIA (NASDAQ:NVDA) sits on the other side of this same customer. Jensen Huang’s strategic partnership with OpenAI to deploy at least 10 gigawatts of NVIDIA systems, combined with the Anthropic scaling on NVIDIA infrastructure with an initial 1 gigawatt commitment, gives NVIDIA a diversified frontier-lab book. NVIDIA’s Q2 FY2027 revenue of $96.22 billion, up 105.8% year over year, and Q3 guidance of $108 billion spread that concentration across more customers and more geographies.

The market treated it accordingly Thursday. NVDA traded up 2% to $227.88 while Broadcom sold off. NVIDIA’s diversified customer base insulates it from the single-customer exposure weighing on Broadcom.

Anthropic Risk Layer One more wrinkle worth pricing in: Anthropic disclosed that foreign AI labs used 24,000 fraudulent accounts to distill its Claude models. Model-distillation risk is now a real line item for any lab preparing to go public.

What to Watch If you own Broadcom because you believe in the $230 billion fiscal 2028 AI number, you are effectively long an Anthropic IPO that has not been filed. Cramer’s framing is blunt, and the price action Thursday says the market heard him. Watch for two things: any formal Anthropic S-1 filing, and Broadcom’s fiscal Q4 report scheduled for December 9, 2026, where the customer mix behind that $115 billion FY27 setup gets its first real update. Cramer said Anthropic is the stock you cannot buy. For AVGO holders, it may be the only one that matters.

Data Sources Cramer’s CNBC Squawk on the Street appearance was the source for the "Anthropic or bust" framing and the "jaw drop" characterization of Tan’s fiscal 2028 guidance. Broadcom’s Q3 FY2026 earnings call transcript provided the customer-by-customer gigawatt roadmap and the $115B/$230B AI revenue trajectory. Broadcom’s Q3 FY2026 8-K filing supplied revenue, EPS, and the customer-concentration risk language. Intraday price performance for AVGO and NVDA came from public market data. Contact [email protected] for any questions or corrections.

A month has gone by since the last earnings report for Archer Daniels Midland (ADM - Free Report) . Shares have added about 10.1% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is ADM due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

Archer Daniels Q2 Earnings Beat on Crushing and Ethanol StrengthArcher Daniels posted second-quarter 2026 adjusted earnings of $1.84 per share, up 98% year over year. The figure surpassed the Zacks Consensus Estimate of $1.42 by 29.6%. On a reported basis, earnings were $1.87 per share, substantially up from 45 cents in the year-ago quarter.

Revenues increased 7.1% to $22.68 billion and beat the consensus estimate of $22.38 billion. Results benefited from margin expansion in Ag Services and North American crushing and robust ethanol economics.  Global oilseed volumes increased roughly 5% compared with the prior-year quarter.

Total segment operating profit increased 75% year over year to $1.5 billion, reflecting broad-based growth across all three operating segments.

Archer Daniels' Revenue Mix Shows AS&O StrengthAg Services and Oilseeds revenues increased 10.1% year over year to $17.9 billion. Carbohydrate Solutions revenues declined 1.3% to $2.8 billion, while Nutrition revenues fell 4.6% to $1.9 billion. Other Business revenues decreased 5.4% to $106 million. The Zacks Consensus Estimate for revenues is pegged at $17.5 billion for Ag Services and Oilseeds, $2.9 billion for Carbohydrate Solutions and $2 billion for Nutrition.

The company processed 9.5 million metric tons of oilseeds, up 4.7% from the prior-year quarter and surpassed the Zacks Consensus Estimate of 9.3 million metric tons. Corn processing volumes rose 2.6% to 4.7 million metric tons. Higher asset utilization supported the improvement in global oilseed volumes.

ADM's Oilseeds Profit More Than DoublesAg Services and Oilseeds operating profit surged 129% to $867 million. Results included roughly $100 million of net positive mark-to-market and timing impacts, mainly within Crushing. Margin expansion in Ag Services and North American crushing provided the primary lift.

Ag Services operating profit climbed 159% to $293 million as ADM leveraged its global asset network and benefited from increased soybean exports and the return of its Barcarena, Brazil, terminal to full operations. Crushing profit substantially jumped to $363 million from $33 million, supported by stronger biofuel margins, elevated energy prices and record meal exports from Brazil and the United States.

Archer Daniels Gains From Strong Ethanol MarginsCarbohydrate Solutions operating profit increased 22% year over year to $411 million. Robust North American ethanol margins, policy incentives, elevated energy prices and lower U.S. corn prices improved ethanol’s economics relative to competing blendstocks. These conditions supported higher domestic blend rates and favorable industry exports.

Starches and Sweeteners operating profit rose 7% year over year to $326 million as stronger wet-milling ethanol margins offset lower liquid sweetener volumes and margins. Vantage Corn Processors’ profit increased 158% year over year to $85 million, aided by strengthening dry-milling ethanol margins and effective risk management.

ADM's Nutrition Recovery Builds MomentumNutrition operating profit advanced 51% year over year to $172 million, with improvement across Human Nutrition and Animal Nutrition. Human Nutrition operating profit increased 51% to $139 million, driven by Flavors growth, seasonal momentum and continued progress at the Decatur East plant.

Animal Nutrition operating profit grew 50% to $33 million. The increase reflected operational improvements and benefits from portfolio actions completed during 2025. The segment’s performance extended ADM’s recovery beyond its commodity-processing businesses.

Archer Daniels’ Other FinancialsThe company ended the quarter with cash and cash equivalents of $1.1 billion, long-term debt, including current maturities, of $7.6 billion, and shareholders’ equity of $23.6 billion. As of June 30, 2026, ADM generated $1.3 billion in cash from operating activities. It paid dividends of $510 million in the reported quarter.

Archer Daniels Raises Its 2026 OutlookADM raised its 2026 adjusted earnings guidance to approximately $5.15-$5.60 per share from the previous range of $4.15-$4.70. The revised outlook assumes year-over-year improvement in crushing and ethanol, supported by disciplined execution and a constructive margin environment.

Management tied the stronger outlook primarily to finalized renewable volume obligations under the U.S. Renewable Fuel Standard, global trade dynamics and higher energy prices. The company continues to project 2026 capital expenditures of $1.3-$1.5 billion while monitoring macroeconomic, geopolitical, policy and trade conditions.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 14.23% due to these changes.

VGM ScoresCurrently, ADM has a subpar Growth Score of D, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise ADM has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry PlayerADM belongs to the Zacks Agriculture - Operations industry. Another stock from the same industry, Corteva, Inc. (CTVA - Free Report) , has gained 14.4% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Corteva, Inc. reported revenues of $6.38 billion in the last reported quarter, representing a year-over-year change of -1.2%. EPS of $2.30 for the same period compares with $2.20 a year ago.

Corteva, Inc. is expected to post a loss of $0.42 per share for the current quarter, representing a year-over-year change of -82.6%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Corteva, Inc.. Also, the stock has a VGM Score of F.

A month has gone by since the last earnings report for Fidelity National Information Services (FIS - Free Report) . Shares have lost about 2.3% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Fidelity National due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Fidelity National Information Services, Inc. before we dive into how investors and analysts have reacted as of late.

FIS Beats Q2 Earnings on Banking Solutions Strength, Cuts 2026 Outlook

Fidelity National reported second-quarter 2026 adjusted earnings per share (EPS) of $1.48, which beat the Zacks Consensus Estimate by 0.7%. The bottom line advanced 8.8% year over year.

Revenues amounted to $3.4 billion, which improved 29% year over year. The top line missed the consensus mark by 0.2%.

The quarterly earnings were driven by strong growth in the Banking Solutions segment and steady performance in the Capital Market Solutions segment, supported by recurring revenue growth, margin expansion and acquisition benefits. However, the upside was partly offset by a higher cost of revenues and increased selling, general and administrative expenses.

FIS’ Q2 PerformanceThe cost of revenues increased 32.4% year over year to $2.2 billion in the second quarter. SG&A expenses of $684 million rose 19.6% year over year. Net interest expenses of $200 million increased 81.8% from the prior-year quarter’s figure.

Adjusted EBITDA was $1.4 billion, up 35% year over year. Adjusted EBITDA margin increased 193 basis points year over year to 41.7%, primarily driven by acquisitions, a favorable business mix and cost savings initiatives.

Q2 Segmental Update of Fidelity NationalRevenues from the Banking Solutions segment totaled $2.5 billion, increasing 44% year over year and matching the Zacks Consensus Estimate. The segmental results benefited from solid margin expansion. Adjusted EBITDA margin improved 179 bps year over year to 45.8%, supported by cost management and a favorable revenue mix.

The Capital Market Solutions segment’s revenues advanced 3.5% year over year to $810 million, marginally missing the Zacks Consensus Estimate by 0.2%. Strong recurring revenue growth benefited the metric. Adjusted EBITDA margin of 51.9% contracted 32 bps year over year.

The Corporate and Other segment recorded revenues of $84 million, down 26% year over year. Adjusted EBITDA loss was $147 million.

FIS’ Q2 Financial UpdateFidelity National exited the second quarter of 2026 with cash and cash equivalents of $744 million, up from $599 million as of 2025-end. Total assets of $44.1 billion increased from $33.5 billion at the end of 2025.

Long-term debt, excluding the current portion, amounted to $15.4 billion, up from $9.1 billion as of Dec. 31, 2025. The current portion of long-term debt totaled $1.5 billion. Short-term borrowings totaled $4.2 billion at the end of the reported quarter.

Total equity of $16 billion increased from $13.9 billion at 2025-end.

Fidelity National generated $493 million in net cash from operations, representing a 29.1% year-over-year increase. Adjusted free cash flow totaled $525 million, up 220% year over year.

FIS’ Share Repurchase & Dividend UpdateThe company returned $270 million to shareholders, including $42 million through share repurchases and $228 million in dividend payments.

FIS’ Key Expectations for Q3’26Management forecasts revenues between $3.415 billion and $3.445 billion. Adjusted EBITDA is projected to be in the range of $1,460-$1,480 million. Adjusted EPS is estimated to be between $1.58 and $1.62.

FIS Updates 2026 GuidanceRevenues are now expected to be $13.63-$13.70 billion, down from the prior guidance of $13.77-$13.85 billion, implying 29-30% adjusted revenue growth.

Adjusted EBITDA is projected to be $5.73-$5.79 billion compared to the earlier outlook of $5.80-$5.86 billion. Adjusted EBITDA margin is anticipated to be in the range of 41.8-42.4% (previously 42.1-42.3%).

Adjusted EPS is forecast in the range of $6.15-$6.24, lowered from the prior guidance of $6.22-$6.32. The midpoint implies about 7.7% year-over-year growth from $5.75 reported in 2025.

Free cash flow guidance has been raised to $2.15-$2.25 billion from the previous $2.05-$2.15 billion. The company now expects free cash flow growth of 33-39% year over year.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.

VGM ScoresCurrently, Fidelity National has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Fidelity National has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

Performance of an Industry PlayerFidelity National belongs to the Zacks Financial Transaction Services industry. Another stock from the same industry, Visa (V - Free Report) , has gained 2.7% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Visa reported revenues of $11.63 billion in the last reported quarter, representing a year-over-year change of +14.4%. EPS of $3.32 for the same period compares with $2.98 a year ago.

Visa is expected to post earnings of $3.43 per share for the current quarter, representing a year-over-year change of +15.1%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.1%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Visa. Also, the stock has a VGM Score of F.

Key Takeaways Chubb's P&C underwriting income rose 18.8% to $1.94 billion, while its combined ratio improved to 83.8%.CB's adjusted net investment income reached a record $1.88 billion, up 11.4% year over year.Chubb returned $1.37 billion to shareholders in Q2, bringing first-half capital returns to $2.90 billion. Shares of Chubb Limited (CB - Free Report) are trading at a premium compared with the industry. Its trailing 12-month price-to-book value of 1.62X is higher than the industry average of 1.43X. However, it currently carries a Value Score of B.

The premium valuation reflects investors' confidence in Chubb's strong profitability, underwriting discipline and growth prospects. However, the higher multiple raises the question of whether the company's fundamentals are strong enough to justify the premium.

Image Source: Zacks Investment Research

Shares of some of its peers, like The Travelers Companies, Inc. (TRV - Free Report) , W.R. Berkley Corporation (WRB - Free Report) and The Progressive Corporation (PGR - Free Report) , are trading at a multiple higher than the industry average.

CB’s Strong Return on EquityReturn on equity (ROE) for the trailing 12 months was 14.5%, significantly above the industry's 7.5%. Core operating return on tangible equity was 21.2% in the second quarter of 2026. Moreover, ROE has remained around 14% over the past three and five years, reflecting the company's consistent ability to generate returns from shareholders' funds.

CB Is an OutperformerChubb shares have gained 21.3% in the past year, outperforming the industry’s growth of 0.8%.  

Shares of other insurers, including TRV, have gained 31.1%, while PGR and WRB have lost 11.1% and 6.5%, respectively, in the past year.

1-Year Price Performance: CB, TRV, WRB, PGR & Industry

Image Source: Zacks Investment Research

CB’s Growth Projection EncouragesThe Zacks Consensus Estimate for Chubb’s 2026 earnings per share (EPS) indicates a year-over-year increase of 10.3%. The consensus estimate for revenues is pegged at $64.34 billion, implying a year-over-year improvement of 7.3%.

The consensus estimate for 2027 EPS and revenues indicates an increase of 5.6% and 4.1%, respectively, from the corresponding 2026 estimates. The expected long-term earnings growth is pegged at 7.7%.

Optimist Analyst Sentiment on CBThe company has witnessed 13 upward earnings estimate revisions for 2026 over the past 60 days, against no movement in the opposite direction. For 2027, it has witnessed five upward revisions against one downward movement. Thus, the Zacks Consensus Estimate for 2026 and 2027 earnings have moved up 2.7% and 0.2%, respectively, over the same time frame.

Image Source: Zacks Investment Research

Factors That Benefit CB StockChubb's underwriting operations remain a major earnings driver. The company prioritizes profitability over premium growth by exiting inadequately priced business, particularly in large-account property insurance. P&C underwriting income increased 18.8% year over year to $1.94 billion in the second quarter of 2026, while the combined ratio improved to 83.8% from 85.6% in the prior-year quarter, reflecting strong underwriting profitability.

Chubb continues to benefit from broad-based premium growth across its businesses, supported by strong performance in its middle-market and international commercial businesses. Middle-market and small commercial premiums increased 8.9% in the second quarter, while overseas commercial insurance premiums rose 8.8%.

CB pursues strategic mergers and acquisitions to diversify its portfolio, add capabilities and synergies, and expand its geographic footprint. Acquisitions, including Catalyst Aviation Insurance and Liberty Mutual's operations in Thailand and Vietnam, have strengthened its product offerings, distribution network and presence in key international markets. Continued investments in AI, digital capabilities and distribution, along with strong broker relationships, are driving new business growth and improve renewal rates.

Higher investment income, supported by the company's fixed-income and alternative asset portfolios, provides an additional source of earnings growth alongside underwriting operations. Adjusted net investment income reached a record $1.88 billion in the second quarter of 2026, up 11.4% year over year.

Chubb's strong cash generation supports shareholder returns and continued capital deployment. The company returned $1.37 billion to shareholders in the second quarter of 2026 through dividends and share repurchases, bringing total capital returned in the first six months to $2.90 billion.

Chubb continues to generate strong growth in book value. As of 30 June 2026, tangible book value per share rose 17.1% to $131.93. The continued growth in book value and tangible book value reflects the company's strong earnings generation and supports the case for its valuation.

Risks for CBChubb remains exposed to catastrophe losses from hurricanes, wildfires, earthquakes and other severe events, which induce volatility in underwriting profitability and affect the combined ratio.  Pretax catastrophe losses totaled $475 million in the second quarter of 2026.

Softening commercial insurance pricing remains a headwind for Chubb, as continued rate declines could weigh on premium growth and profitability.

ConclusionChubb is positioned to deliver continued earnings and book-value growth through strong underwriting profitability, middle-market and overseas commercial expansion, higher investment income and disciplined capital management. Favorable estimates, optimistic analyst sentiment and higher ROE are other positives. A VGM Score of A instils confidence.

While the premium valuation appears justified by Chubb's profitability and growth profile, continued earnings growth and underwriting discipline will be important to sustain the higher multiple. Catastrophe losses and softer commercial pricing remain risks. It is wise to retain this Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It has been about a month since the last earnings report for Devon Energy (DVN - Free Report) . Shares have added about 16.5% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Devon Energy due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Devon Energy Corporation before we dive into how investors and analysts have reacted as of late.

Devon Q2 Earnings Surpass Estimates on Strong Oil Output and Pricing

Devon Energy Corporation reported second-quarter 2026 adjusted earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.30 by 20.77%.

GAAP earnings were $2.03 per share, up 44% from $1.41 a year ago.

Total RevenuesRevenues of $7.41 billion surpassed the consensus estimate of $6.29 billion by 17.81% and increased 73.1% year over year. Strong oil pricing and contributions from the Coterra Energy merger supported the results.

Oil, gas and natural gas liquids sales totaled $5.11 billion compared with $2.71 billion in the year-ago quarter. Marketing and midstream revenues increased to $1.90 billion from $1.34 billion.

Oil, gas and NGL derivatives generated revenues of $414 million compared with $236 million a year earlier. The latest figure included $530 million of positive derivative valuation changes, partly offset by $116 million of cash settlement losses.

Devon’s Production PerformanceTotal production averaged 1,359 thousand barrels of oil equivalent per day (MBoe/d), up 61.6% year over year from 841,000 Boe/d. Devon completed its merger with Coterra on May 7, meaning the quarterly figures included combined operations for part of the period. The production level was 1.6% higher than the midpoint of management’s guidance.

Oil production rose 30% year over year to 503,000 barrels per day. NGL output climbed 41.4% to 314,000 barrels per day, while natural gas production increased to 3,252 million cubic feet per day from 1,388 million cubic feet. Better-than-expected well performance in the Delaware Basin supported oil and gas volumes.

DVN Benefits From Strong Oil RealizationsRealized oil prices, including cash settlements, were up 39.9% year over year to $88.09 per barrel from $62.97 in the prior-year quarter. Excluding hedges, oil realizations were $95.10 per barrel.

Realized NGL prices increased to $22.70 per barrel from $17.82. However, realized natural gas prices, including cash settlements, declined to $1.05 per thousand cubic feet from $1.56. Regional Waha pricing was pressured by infrastructure constraints in the Delaware Basin.

Devon Keeps Capital Spending DisciplinedCapital expenditures were $1.27 billion, 2% below the midpoint of management’s guidance. The company placed 120 net operated wells online during the quarter, with an average lateral length of 10,800 feet.

The Permian accounted for $731 million of capital spending, followed by $196 million in the Rockies. Eagle Ford, Anadarko and Marcellus expenditures were $97 million, $129 million and $70 million, respectively. Devon acquired 16,300 net Delaware Basin acres for $2.6 billion, adding approximately 400 top-tier locations.

DVN Generates Robust Free Cash FlowNet cash from operating activities was $3.67 billion compared with $1.55 billion a year ago. Adjusted operating cash flow was $2.9 billion, while adjusted free cash flow totaled roughly $1.7 billion, excluding after-tax restructuring costs.

Devon returned $1.06 billion through dividends, share repurchases and debt retirement. It repurchased 4.3 million shares for $197 million and paid $366 million in dividends. The quarterly fixed dividend was raised 33% to 32 cents per share.

Devon Provides GuidanceFor the third quarter of 2026, total production is expected between 1,660 MBoe/d and 1,690 MBoe/d. Oil production is projected in the range of 550,000-560,000 barrels per day. Third-quarter capital expenditures are anticipated between $1.4 billion and $1.5 billion.

Devon maintained its full-year guidance, calling for total production of 1,364 MBoe/d to 1,398 MBoe/d and capital spending of $4.8-$5 billion. 2026 Oil production is expected to be in the range of 495,000-505,000 barrels per day. Natural gas production for 2026 is expected to be in the range of 3,300-3,400 million cubic feet per day.

Management remains on track to achieve at least $1 billion in annual pre-tax merger synergies on a run-rate basis by the end of 2027.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 9.24% due to these changes.

VGM ScoresCurrently, Devon Energy has a great Growth Score of A, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of B on the value side, putting it in the second quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Devon Energy has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerDevon Energy belongs to the Zacks Oil and Gas - Exploration and Production - United States industry. Another stock from the same industry, Range Resources (RRC - Free Report) , has gained 11.4% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Range Resources reported revenues of $795.3 million in the last reported quarter, representing a year-over-year change of +8.5%. EPS of $0.79 for the same period compares with $0.66 a year ago.

Range Resources is expected to post earnings of $0.67 per share for the current quarter, representing a year-over-year change of +17.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +5.6%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Range Resources. Also, the stock has a VGM Score of B.

It has been about a month since the last earnings report for Lucid Group (LCID - Free Report) . Shares have lost about 29.7% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Lucid Group due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Lucid Group, Inc. before we dive into how investors and analysts have reacted as of late.

LCID Q2 Earnings MissLucid reported a second-quarter 2026 loss of $3.30 per share, wider than the year-ago loss of $2.80 as well as the Zacks Consensus Estimate of a loss of $2.72.

Revenues surged 56.2% year over year to $405 million and beat the consensus estimate of $323 million by 25.4%. Higher vehicle deliveries, improved product mix and increased regulatory credit sales supported the top line.

Deliveries and Product Mix Lift SalesLucid produced 4,774 vehicles during the quarter, up 24% year over year. Production declined 13% sequentially as management deliberately reduced output to align manufacturing with near-term demand and limit further inventory growth.

Deliveries rose to 3,953 vehicles, up 19% year over year and 28% sequentially. Lucid Gravity accounted for the majority of volumes. Revenues also benefited from a 3.7% sequential increase in average selling price and a $25 million increase in regulatory credit sales. Deliveries in the Middle East improved during the quarter.

Gross Margin Stays Deeply NegativeGross margin was negative 105%, compared with negative 110% in the first quarter and negative 105% a year ago. Lower production reduced fixed-cost absorption and raised conversion costs per vehicle, offsetting the benefits of higher revenues and improved pricing.

Results included roughly $300 million of inventory impairment charges, which reduced gross margin by 74 percentage points. The charge reflected a reassessment of inventory carrying values and expected demand. Lucid also reduced firm purchase commitments to lower future inventory obligations and cash requirements.

LCID Targets $1.4B in Cash Flow ImprovementsAdjusted EBITDA loss widened to $901.1 million from $632.1 million in the year-ago quarter. Operating expenses included $321.3 million of research and development costs, $300.4 million of selling, general and administrative expenses and $33.7 million of workforce-reduction charges.

Management identified $1.4 billion of cash flow improvements for 2026. The plan includes projected inventory savings of $600-$800 million, capital expenditure reductions of about $500 million and operating expense savings of roughly $200 million. Lucid’s U.S. workforce reduction and elimination of the second shift at its Arizona factory are expected to generate $158 million in annualized savings.

Lucid Advances Robotaxi and AMP-2 ProgramsLucid’s robotaxi program with Uber and Nuro moved deeper into testing and validation. The engineering fleet includes nearly 100 vehicles operating across the San Francisco Bay Area and Houston. Production-validation Gravity vehicles have begun reaching partners, with regular production expected in the fourth quarter and service launch targeted for late 2026.

The AMP-2 factory in Saudi Arabia has shifted from construction to industrialization. Manufacturing systems for stamping, body, paint and final assembly are being installed and tested. Lucid expects the facility to be ready for production in early 2027 and for midsize production in the second half of that year.

Balance Sheet and Liquidity PositionLucid ended the June quarter with $3 billion of total liquidity, including about $800 million of cash and investments and $2.2 billion of available borrowing capacity.

Free cash flow was negative $1.48 billion, compared with negative $1.01 billion a year earlier. Net cash used in operating activities totaled $1.22 billion, while capital expenditures were $253.8 million. Inventory increased to $1.38 billion from $1.11 billion at the end of 2025.

LCID Withholds GuidanceLucid did not provide quantitative financial guidance. Management expects third- and fourth-quarter production to remain below second-quarter levels as AMP-1 operates with one shift through year-end.

Deliveries are expected to exceed production during the second half as Lucid works down finished-vehicle inventory. Management anticipates sequential delivery growth consistent with normal seasonality, though at a more moderate pace than in the prior year. The company expects its current liquidity and operational measures to provide runway well into 2027.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted 5.97% due to these changes.

VGM ScoresCurrently, Lucid Group has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision looks promising. Notably, Lucid Group has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerLucid Group is part of the Zacks Automotive - Domestic industry. Over the past month, Tesla (TSLA - Free Report) , a stock from the same industry, has gained 11%. The company reported its results for the quarter ended June 2026 more than a month ago.

Tesla reported revenues of $28.24 billion in the last reported quarter, representing a year-over-year change of +25.5%. EPS of $0.33 for the same period compares with $0.40 a year ago.

Tesla is expected to post earnings of $0.47 per share for the current quarter, representing a year-over-year change of -6%. Over the last 30 days, the Zacks Consensus Estimate has changed -1%.

Tesla has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Wix.com Ltd. (NASDAQ: WIX) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Wix securities between February 19, 2025 and May 12, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/WIX.

Wix Case Details

According to the Complaint, the Company made false and misleading statements to the market. Specifically, Defendants failed to disclose that:
      (1)   Wix had overstated the competitiveness and performance of its AI product offerings relative to competing products;
      (2)   the Company had understated the costs associated with developing and promoting its AI product offerings;
      (3)   as a result, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and
      (4)   accordingly, Defendants' public statements were materially false and misleading at all relevant times.

What's Next for Wix Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/WIX. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Wix you have until September 22, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Wix Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Wix Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

The fast-food industry is facing a severe reality check. Menu price hikes are pricing out the core lower-income demographic, causing a decline in foot traffic across the sector. Yet amid this crisis, one operator just executed a masterclass in corporate defense.

Yum! Brands Today

$152.23 +0.96 (+0.63%)

As of 01:53 PM Eastern

This is a fair market value price provided by Massive. Learn more.

$137.33▼

$170.141.97%

19.17

$174.65

Yum! Brands NYSE: YUM successfully offloaded its underperforming Pizza Hut asset outside Mainland China for about $1.5 billion.

By allowing a private equity buyer to absorb the legacy brand's looming turnaround risk, Yum! Brands quietly transitions into a high-return, pure-play franchising model.

Get Yum! Brands alerts:

With Yum! Brands shielding its remaining portfolio behind an approximately $4 billion stock buyback, investors are witnessing a strategic pivot deployed right at the onset of brutal macro headwinds.

Shedding the stagnant pizza chain fundamentally changes the business's financial trajectory, setting the stage for a shift in how Wall Street values Yum! Brands stock.

Addition by Subtraction: Cutting the CrustCorporate restructuring often looks messy on the surface, but the financial mechanics underneath reveal a clear path to value creation. The sale of the Pizza Hut brand to LongRange Capital serves as a textbook example of addition by subtraction. Factoring in the separate Mainland China transaction, the total Pizza Hut carve-out proceeds reach approximately $2.7 billion.

For years, Pizza Hut operated as a chronic drag on system-wide metrics, actively suppressing the growth generated by Taco Bell and KFC. Public markets historically penalize parent companies burdened by capital-intensive turnaround projects.

Investors saw this reflected in the numbers, with the return on equity for Yum! Brands recently dipping to -24.57%. That figure signals severe capital inefficiency prior to the asset sale. By transferring the operational weight of Pizza Hut to private equity, Yum! Brands protects its consolidated margin profile. Private equity buyers can pursue extensive operational restructuring without the immediate pressures of quarterly public-market reporting.

For Yum! Brands, removing this drag clears the path for a re-rating of its stock. The business is now heavily concentrated in higher-margin, faster-growing assets. Its streamlined franchising model will require less overhead, allowing management to deploy capital much more aggressively toward concepts that actually drive unit growth.

Starving the Crisis: Insulating Taco Bell and KFCInvestors should connect the macro environment to the catalyst to understand why this sale is so critical right now. The broader quick-service restaurant space is experiencing significant demand reduction. Fast-food operators long believed their business models were recession-resistant, leaning on aggressive pricing power to offset inflation. That strategy has hit a wall. Anecdotal channel checks reveal localized traffic drops, with some Taco Bell locations reporting foot traffic down by about half in late summer.

Coinciding with the ownership change, Pizza Hut chief executive officer Aaron Powell abruptly resigned, leaving Eduardo Luz to serve as interim chief executive. While executive transitions regularly accompany private equity buyouts, a sudden departure at a flagship property highlights the internal volatility and execution risk that legacy chains face. The consumer base is retreating. Short interest in Yum! Brands rose over 14% by mid-August as retail skepticism grew.

However, the retail panic misses the genius of the timing. Management pegged the demand trends early. Selling the pizza chain right as traffic falls off a cliff helps to insulate the surviving KFC and Taco Bell portfolios from the heaviest capital requirements. Yum! Brands traded an operational headache for a substantial influx of liquidity, passing the execution risk of a turnaround to LongRange Capital just as the broader consumer environment deteriorates.

Serving Up Yield: A $4B Capital DietYum! Brands' leaner operational model generates excess free cash flow, which management is routing back to shareholders. The board of directors recently authorized an approximately $4 billion share repurchase program. At current valuations, this provides the capacity to retire roughly 9.4% of outstanding equity.

93rd Percentile

Moderate Buy

14.9% Upside

Healthy

Strong

0.97 Selling Shares

7.86%

See Full Analysis

When a company shrinks its share count by nearly a tenth, it artificially boosts earnings per share, even if top-line revenue suffers. This buyback serves as a structural defense mechanism against current macro headwinds.

Income investors also gain a highly predictable asset. Yum! Brands maintains an eight-year consecutive dividend growth streak, boasting an 8.6% five-year annualized growth rate. Supported by a highly conservative payout ratio of 37%, the annual dividend provides a sustainable yield of near 2%. This capital return profile remains highly durable despite the broader industry volatility.

While retail traders and short sellers seem to be fixating on the executive departure and recent insider selling, institutional money is rotating into the stock. Recent filings show concentrated block buying by multiple institutions. These sophisticated allocations indicate a strong long-term appetite for Yum! Brands' streamlined corporate structure.

Digesting Yum! Brands New StrategyThe fast-food industry will likely face prolonged discounting wars as operators scramble to win back alienated customers. Margin compression across the sector appears inevitable as companies sacrifice pricing power for transaction volume. However, companies that proactively shed underperforming assets and aggressively shrink their equity float position themselves to survive the downturn and emerge significantly stronger.

Cautious investors may prefer to wait for a broader market pullback before taking a position, while those with a long-term horizon might consider adding Yum! Brands to their watchlists as the financial benefits of the streamlined franchising model take effect.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Yum! Brands Right Now?Before you consider Yum! Brands, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Yum! Brands wasn't on the list.

While Yum! Brands currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

A month has gone by since the last earnings report for Celanese (CE - Free Report) . Shares have added about 8.2% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Celanese due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

Celanese’s Q2 Earnings Beat Estimates on Pricing and ExecutionCelanese reported second-quarter 2026 adjusted earnings of $2.45 per share, up 71.3% from $1.43 a year ago. The bottom line surpassed the Zacks Consensus Estimate of $2.21 by 10.9%. 

Net sales rose 8.7% year over year to $2.75 billion and beat the consensus estimate of $2.65 billion by 3.7%. Strong pricing and mix, commercial execution and momentum in medical and electronics supported the results. Sequentially, sales increased 18%, reflecting a 4% volume gain and a 14% pricing increase. 

Segment HighlightsEngineered Materials recorded net sales of $1.45 billion, up 9% sequentially. It beat our estimate of $1.42 billion. The segment generated an operating profit of $156 million and adjusted EBIT of $234 million. Operating profit declined from $164 million a year ago, while adjusted EBIT increased from $213 million. 

The Acetyl Chain posted net sales of $1.33 billion, up 28% sequentially. It topped our estimate of $1.22 billion. The segment delivered an operating profit of $237 million, up from $153 million in the prior-year quarter. Adjusted EBIT increased to $321 million from $195 million. 

FinancialsCelanese ended the second quarter with cash and cash equivalents of $1.36 billion. Long-term debt was $10.70 billion. Cash provided by operating activities totaled $209 million and free cash flow was $140 million. 

OutlookCelanese expects third-quarter adjusted earnings in the range of $1.35-$1.75 per share. For 2026, the company continues to expect adjusted earnings of approximately $6 per share. Celanese also maintained its full-year free cash flow guidance of $700-$800 million. 

Management expects growth initiatives and productivity, portfolio and footprint actions to support performance in 2026. These measures are also intended to create additional earnings growth opportunities in the years ahead while strengthening cash generation and supporting deleveraging.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -6.76% due to these changes.

VGM ScoresAt this time, Celanese has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock has a score of A on the value side, putting it in the top 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Celanese has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

A month has gone by since the last earnings report for ViaSat (VSAT - Free Report) . Shares have lost about 13.7% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is ViaSat due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Viasat Inc. before we dive into how investors and analysts have reacted as of late.

Viasat Q1 Earnings Beat Estimates Despite Lower Y/Y Revenues 

Viasat reported mixed first-quarter fiscal 2027 results, with revenues missing the Zacks Consensus Estimate and earnings beating the consensus estimate.

The company reported a year-over-year revenue decline, reflecting ongoing headwinds in portions of its legacy commercial services portfolio and lower IP licensing revenues. However, its bottom line improved as reduced interest expense, driven by continued debt repayment, outweighed the impact of lower revenues.

Net Income

Viasat reported a net loss of $51.7 million or a loss of 38 cents per share compared with a net loss of $56.4 million or a loss of 43 cents per share in the prior-year quarter. The narrower loss was due to lower interest expense during the quarter.

Excluding non-recurring items, Viasat reported non-GAAP net income of $24.5 million or 17 cents per share compared with $23.1 million or 17 cents per share in the prior-year period. The bottom line beat the Zacks Consensus Estimate of 10 cents.

Revenues

Revenues declined to $1.16 billion from $1.17 billion. The figure missed the consensus estimate of $1.2 billion. Product revenues were $324.1 million, down from $344.7 million in the year-ago quarter. Service revenues increased to $832.4 million from $826.4 million a year ago.

Revenues from the Communication Services segment were $825.1 million, down from $827.4 million in the prior-year quarter. The marginal revenue decline reflected lower contributions from residential fixed broadband and maritime services, which offset continued growth in aviation and government Satellite Communications. The segment’s adjusted EBITDA decreased to $311.3 million from $321.5 million.

Revenues from the Defense and Advanced Technologies (DAT) segment were $331.5 million, down 4% year over year, primarily due to weaker contributions from Advanced Technologies & Other and Space and Mission Systems, despite strong Tactical Networking growth. Adjusted EBITDA decreased to $69.9 million from $86.9 million in the year-ago quarter.

Other Details

In the June quarter, Viasat reported an operating income of $47.3 million compared with $46.7 million in the prior-year quarter. Adjusted EBITDA was $381.1 million, down from $408.5 million in the year-ago quarter. The net contract awards increased to $1.3 billion from $1.18 billion a year ago, while the backlog increased 19% year over year to $4.22 billion.

Cash Flow & Liquidity

During the first quarter of fiscal 2027, Viasat generated an operating cash flow of $260.6 million compared with $258.5 million in the prior-year period. As of June 30, 2026, the company had $1.74 billion in cash and cash equivalents, with a net debt of $4.83 billion.

Outlook

For fiscal 2027, management expects mid-single-digit revenue growth and flat to slightly up adjusted EBITDA year over year. Viasat anticipates the Communication Services segment’s low single-digit year-over-year revenue performance, due to continued growth in aviation services, offset by a decline in FS&O. DAT revenue growth is anticipated to be in the mid-teens, primarily driven by strong growth in information security and cyber defense, as well as space and mission systems and tactical networking.

Capital expenditure is expected to be between $950 million and $1 billion (including approximately $250-$300 million for Inmarsat-related capital expenditures). The company’s operating cash flow is expected to be flat year over year, and the free cash flow is anticipated to be approximately $180 million (excluding the benefit of the Ligado lump sum payments, as they are non-recurring).

How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended downward during the past month.

The consensus estimate has shifted -13.33% due to these changes.

VGM ScoresCurrently, ViaSat has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of A on the value side, putting it in the top 20% for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, ViaSat has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerViaSat is part of the Zacks Wireless Equipment industry. Over the past month, Nokia (NOK - Free Report) , a stock from the same industry, has gained 2.7%. The company reported its results for the quarter ended June 2026 more than a month ago.

Nokia reported revenues of $5.6 billion in the last reported quarter, representing a year-over-year change of +8.5%. EPS of $0.08 for the same period compares with $0.05 a year ago.

Nokia is expected to post earnings of $0.08 per share for the current quarter, representing a year-over-year change of +14.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Nokia. Also, the stock has a VGM Score of D.

It has been about a month since the last earnings report for Wynn Resorts (WYNN - Free Report) . Shares have lost about 9.5% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Wynn due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.

Wynn Resorts Q2 Earnings & Revenues Beat on Palace StrengthWynn Resorts reported second-quarter 2026 results, with earnings and revenues beating the Zacks Consensus Estimate. The top and bottom lines increased on a year-over-year basis.

Management highlighted healthy demand across the business, including a monthly Adjusted Property EBITDAR record in Las Vegas during May and strong performance in Macau. Wynn Palace led the quarter’s growth, with revenues rising 21.1% and Adjusted Property EBITDAR increasing 28.2% year over year.

WYNN’s Q2 Earnings & RevenuesIn the second quarter, the company reported adjusted earnings per share of $1.24, beating the Zacks Consensus Estimate of $1.01 by 22.8%. In the prior-year quarter, Wynn Resorts reported adjusted earnings of $1.09 per share.

Quarterly operating revenues of $1.86 billion surpassed the consensus mark of $1.84 billion by 0.9%. The top line increased 6.9% from $1.74 billion reported in the year-ago quarter.

Wynn Palace OperationsIn the second quarter, Wynn Palace’s operating revenues amounted to $653.4 million compared with $539.6 million in the prior-year quarter. Casino revenues increased 25.9% year over year to $564.4 million, while food and beverage revenues rose 4.4% to $31.8 million.

Rooms and entertainment, retail and other revenues declined 6% each to $36.2 million and $21.1 million, respectively. Adjusted Property EBITDAR increased to $201.5 million from $157.2 million, with the margin improving to 30.8% from 29.1%.

In the VIP segment, table games turnover declined 32% year over year to $2.77 billion. The VIP table games win rate was 2.97% compared with 2.86% in the prior-year quarter and remained below the property’s expected range of 3.1% to 3.4%.

Mass-market table drop increased 3% to $1.9 billion, while table games win rose 36.9% to $563.3 million. The mass-market table games win percentage improved to 29.7% from 22.3%. RevPAR declined 5.7% to $216, while occupancy was 98.9%.

WYNN’s Wynn Macau OperationsIn the second quarter, Wynn Macau generated operating revenues of $351.1 million compared with $343.8 million reported in the prior-year quarter. Casino revenues increased 2.5% to $300.7 million, while entertainment, retail and other revenues rose 8.7% to $12.7 million.

Rooms and food and beverage revenues declined 3.8% and 1.5% to $20.9 million and $16.8 million, respectively. Adjusted Property EBITDAR declined 1% to $95.5 million from $96.5 million.

VIP table games turnover fell 56.4% year over year to $428.1 million. The VIP win rate declined to 2.58% from 3.41% and remained below the expected range.

Mass-market table drop rose 8.3% to $1.75 billion, and table games win increased 6.9% to $300.2 million. Slot machine handle advanced 18%, while slot machine win climbed 38.6%. RevPAR declined 3.3% to $208.

Wynn Resorts’ Las Vegas OperationsIn the second quarter, operating revenues from Las Vegas Operations totaled $643.2 million compared with $638.6 million in the prior-year quarter. Casino revenues increased 6.5% to $158.1 million, while room revenues edged up 0.1% to $208.1 million.

Food and beverage revenues rose 0.4% to $195.7 million. Entertainment, retail and other revenues declined 6.9% to $81.2 million. Adjusted Property EBITDAR decreased 8.3% to $215.2 million, with the margin contracting to 33.5% from 36.8%.

Table drop increased 4.8% year over year to $638.2 million, while table games win rose 14.8% to $152.7 million. The table games win percentage improved to 23.9% from 21.8%.

RevPAR increased 2.5% to $501, while the average daily rate rose 4.9% to $575. Occupancy declined to 87.1% from 89.2% in the year-ago quarter.

WYNN’s Encore Boston HarborIn the second quarter, Encore Boston Harbor’s operating revenues amounted to $209.3 million compared with $215.7 million in the prior-year quarter. Casino revenues fell 5.9% to $152.1 million.

Rooms and food and beverage revenues increased 9.7% and 7.4% to $25.1 million and $20.1 million, respectively. Entertainment, retail and other revenues declined 3.9% to $12 million.

Adjusted Property EBITDAR decreased 12.2% to $56.1 million from $63.9 million. The table games win percentage fell to 18.1% from 21.3%.

RevPAR increased 9.6% to $412, while the average daily rate rose 9.9% to $445. Occupancy was 92.7% compared with 92.9% in the prior-year quarter.

Wynn Resorts’ Q2 Operating PerformanceIn the second quarter, Adjusted Property EBITDAR totaled $568.3 million compared with $552.4 million in the year-ago quarter. The consolidated margin declined to 30.6% from 31.8%.

Operating income increased to $297.6 million from $264.6 million reported in second-quarter 2025. Net income attributable to Wynn Resorts rose to $140.1 million from $66.2 million reported in the prior year quarter.

WYNN’s Cash Position and Capital ReturnsAs of June 30, 2026, cash and cash equivalents totaled $1.57 billion, excluding $527.4 million of short-term investments held by Wynn Macau. Total current and long-term debt outstanding was $10.72 billion.

The company repurchased 741,098 shares for $75 million during the quarter. Wynn Resorts also declared a cash dividend of 25 cents per share, payable Aug. 28, 2026. Wynn Al Marjan Island is expected to open in September 2027.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates review.

VGM ScoresCurrently, Wynn has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. Following the exact same course, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Wynn has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

A month has gone by since the last earnings report for TransMedics (TMDX - Free Report) . Shares have added about 10.2% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is TransMedics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

TransMedics Q2 Earnings Miss Estimates, Revenues Up Y/YTransMedics delivered earnings per share of 44 cents in the second quarter of 2026, down 52.2% year over year. The figure missed the Zacks Consensus Estimate by 12%.

TMDX Revenue Mix Shows Service StrengthRevenues rose 20.7% year over year to $189.9 million and surpassed the consensus estimate by 3.1%.

Net product revenues totaled $111.2 million, up 15.7% from the prior-year quarter. The improvement was led by higher organ utilization and increased OCS adoption, particularly across the liver and heart businesses.

Service revenues represented roughly 41% of total revenues and increased 28.6% to $78.8 million. Clinical service revenues rose 19.1% to around $36 million. The stronger service contribution reflected broader logistics adoption, pricing adjustments and higher aviation-fleet utilization.

Transplant Logistics’ services revenues for second-quarter 2026 were approximately $41 million, up 39% year over year. TransMedics operated 22 owned aircraft during the quarter and covered 86% of National OCS Program missions requiring air transportation, compared with 82% coverage in the first quarter of 2026. This growth resulted from the broader adoption of TransMedics’ logistics services, increased aviation-fleet utilization and improved operating efficiency.

TMDX’s Margin TrendIn the quarter under review, TransMedics’ gross profit increased 17.2% year over year to $113.2 million. The gross margin contracted 100 basis points (bps) to 60%.

Selling, general and administrative expenses rose 31.2% year over year to $57.8 million. Research, development and clinical trials expenses surged 98.5% year over year to $31.6 million. Total operating expenses of $89.5 million increased 49.1% year over year.

Adjusted operating profit totaled $25.8 million, reflecting a decline of 29.5% from the prior-year quarter. The adjusted operating margin in the second quarter contracted 960 bps to 13.6%.  

TransMedics’ Financial PositionTransMedics exited second-quarter 2026 with cash of $472.7 million compared with $461.7 million at the end of the first quarter. Total long-term debt at the end of second-quarter 2026 was $39.7 million compared with $44.5 million at the end of the first quarter.

Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $41.8 million compared with $88.8 million a year ago.

TransMedics Raises Its Revenue OutlookTransMedics raised the lower end of its 2026 revenue guidance. Revenues are now expected to be between $737 million and $757 million, representing growth of approximately 22% to 25% from the 2025 level. The previous projection called for revenues of $727 million to $757 million.

The outlook excludes contributions from PAD Aviation and assumes no incremental revenues from the ENHANCE Part B and DENOVO clinical programs. Adjusted operating margin, excluding PAD Aviation, is expected to be between 12.5% and 14%, below the company’s prior expectation of approximately 16% because of accelerated OCS Kidney investments.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -31.5% due to these changes.

VGM ScoresAt this time, TransMedics has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise TransMedics has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.

Performance of an Industry PlayerTransMedics is part of the Zacks Medical - Instruments industry. Over the past month, IQVIA Holdings (IQV - Free Report) , a stock from the same industry, has gained 11.8%. The company reported its results for the quarter ended June 2026 more than a month ago.

IQVIA reported revenues of $4.37 billion in the last reported quarter, representing a year-over-year change of +8.7%. EPS of $3.15 for the same period compares with $2.81 a year ago.

IQVIA is expected to post earnings of $3.25 per share for the current quarter, representing a year-over-year change of +8.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

IQVIA has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.

Key Takeaways Recursion is advancing REC-4881 in FAP while pursuing a potential registrational pathway with the FDA.RXRX is expanding its oncology pipeline with REC-1245, REC-617, REC-3565, REC-4539 and REC-7735.Genentech has advanced a neuroscience target from its RXRX collaboration, further validating its platform. Recursion Pharmaceuticals (RXRX - Free Report) uses an AI-driven drug discovery platform, Recursion Operating System (OS), to identify and develop novel therapies across its pipeline. It is advancing several clinical-stage programs, with REC-4881 emerging as its most advanced internal candidate and multiple oncology assets providing additional pipeline diversification.

REC-4881, an allosteric MEK1/2 inhibitor, is being evaluated in a phase Ib/II TUPELO study for familial adenomatous polyposis (FAP), a rare inherited disorder characterized by the development of numerous colorectal polyps. Earlier clinical data showed rapid and durable reductions in polyp burden, which Recursion described as the first clinical validation of the Recursion OS. RXRX has initiated discussions with the FDA on a potential registrational pathway, while additional phase II safety and efficacy data from the TUPELO study are expected in November 2026.

Beyond REC-4881, Recursion is advancing several oncology candidates, including REC-1245 for biomarker-enriched solid tumors and lymphoma, REC-617 for advanced solid tumors and REC-3565 for B-cell malignancies, all of which are currently undergoing early-stage development. REC-4539, an LSD1 inhibitor, also entered clinical-stage development for solid tumors, with potential applicability in hematologic malignancies. Meanwhile, REC-7735, an AI-designed PI3Kα H1047R inhibitor, has received clinical-study clearance and is expected to enter a phase I/II study in the second half of 2026 for selected PIK3CA H1047R-mutant solid tumors, adding another potential catalyst to the pipeline.

Recursion is also advancing REC-102, an ENPP1 inhibitor for hypophosphatasia, following its acquisition of full rights to the program from Rallybio. The oral candidate is designed as a potential disease-modifying treatment for hypophosphatasia and expands Recursion's presence in rare diseases. In addition, Genentech (a wholly owned subsidiary of Roche) recently advanced the first neuroscience target from its collaboration with Recursion into an early discovery program, providing another potential validation of RXRX’s proprietary platform. With multiple clinical programs advancing and several potential catalysts ahead, Recursion’s expanding pipeline could strengthen its long-term growth prospects.

RXRX Faces Competitive Pressure in the TechBio IndustryIn the TechBio space, Relay Therapeutics (RLAY - Free Report) and Schrödinger (SDGR - Free Report) are emerging as strong competitors to Recursion Pharmaceuticals, using computationally driven platforms to discover and develop novel therapies.

RLAY is currently evaluating its lead candidate, zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor, in the phase III ReDiscover-2 study in combination with fulvestrant in previously CDK4/6-treated, PIK3CA-mutated HR+/HER2- advanced breast cancer. It is also planning to initiate a separate late-stage frontline breast cancer study of the candidate, subject to regulatory feedback, while the phase I/II ReInspire study is evaluating zovegalisib in PIK3CA-driven vascular anomalies. Relay Therapeutics is also developing RLY-8161, an NRAS-selective inhibitor, in a phase I/II study for NRAS-mutant melanoma and other solid tumors. In addition, the company is advancing a preclinical, non-inhibitory chaperone program for Fabry disease, as well as early-stage discovery programs across both precision oncology and genetic diseases.

Schrödinger’s lead proprietary pipeline consists of SGR-1505, a MALT1 inhibitor in phase I for relapsed/refractory B-cell malignancies, and SGR-3515, a Wee1/Myt1 inhibitor undergoing phase I development for advanced solid tumors. Both programs were discovered using Schrödinger's computational capabilities, with SGR-3515 showing preliminary clinical activity and SGR-1505 demonstrating encouraging activity in B-cell malignancies in earlier updates. SDGR plans to complete its ongoing early-stage studies while seeking strategic partners to advance SGR-1505 and SGR-3515 beyond phase I.

RXRX’s Stock Price, Valuation & Estimate MovementsYear to date, RXRX shares have lost 17.4% against the industry’s 9.7% growth. During the same time frame, Recursion has also underperformed the S&P 500 and the overall medical sector, as seen in the chart below.

RXRX Mixed Stock PerformanceImage Source: Zacks Investment Research

Recursion is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 1.97, which is less than 3.97 for the industry. The stock is trading significantly below its five-year mean of 3.22.

RXRX Stock ValuationImage Source: Zacks Investment Research

Loss estimates for 2026 have narrowed from 99 cents per share to 92 cents over the past 30 days. During the same time frame, RXRX’s 2027 loss per share estimates have narrowed from 96 cents to 92 cents.

RXRX Estimate MovementImage Source: Zacks Investment Research

Recursion currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It has been about a month since the last earnings report for Entegris (ENTG - Free Report) . Shares have lost about 9.8% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Entegris due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

Entegris Q2 Earnings Beat Estimates, Revenues Rise Y/YEntegris, Inc. reported second-quarter 2026 non-GAAP earnings of 93 cents per share, up 40.9% year over year. The figure beat the Zacks Consensus Estimate of 83 cents by 12.1%, reflecting stronger semiconductor demand, operational execution and accelerating customer capital investment.

Net sales increased 11.5% to $883.2 million and topped the consensus estimate of $840 million by 5.2%. Unit-driven revenues rose 10%, while capital expenditure-related revenues advanced 15%, supported by AI-linked investments across advanced logic, memory and packaging.

ENTG's APS Growth Leads Segment MomentumAdvanced Purity Solutions revenues climbed 17% year over year to $514.6 million. Growth reflected strength across both unit-driven and capital expenditure-related demand, with liquid filtration delivering a fourth consecutive record quarter.

The microenvironments business, led by front-opening unified pods, posted its strongest performance in more than three years. Taiwan benefited from leading-edge logic and advanced packaging expansions, while North America returned to year-over-year growth. Adjusted segment margin expanded to 30.3% from 24.1%.

Entegris' Materials Business Gains SpeedMaterials Solutions revenues rose 4.6% year over year to $371.3 million. Advanced deposition materials, selective etch chemistries and chemical mechanical planarization products drove the increase.

Adjusted segment profit was $77.7 million, up 2.9%, while adjusted segment margin eased to 20.9% from 21.3%. Higher raw-material and logistics costs, along with planned direct-labor investments, were largely offset by manufacturing improvements and productivity initiatives.

ENTG Expands Margins on Better ExecutionAdjusted gross margin expanded to 47.6% from 44.6% a year earlier and improved from 46.9% in the first quarter. Management attributed the sequential gain to operational progress despite investments to support future demand.

Non-GAAP operating expenses increased 8.3% year over year to $203.9 million, mainly due to higher variable compensation tied to stronger business performance. Even so, adjusted operating margin widened to 24.5% from 20.9%, and adjusted EBITDA margin rose to 28.4% from 27.3%.

Entegris Strengthens Cash Flow and LeverageThe company generated operating cash flow of $156.2 million in the second quarter, while capital expenditures were $39.3 million. Free cash flow totaled $120.3 million in the second quarter, representing roughly 14% of sales and more than doubling from $47 million in the year-ago quarter. In the first half of 2026, Entegris generated operating cash flow of $339.2 million and free cash flow of $263.8 million.

ENTG repaid $200 million of debt during the quarter, reducing long-term debt to $3.46 billion. It ended the second quarter with cash and cash equivalents of $353.6 million. The company’s net leverage improved to 3.4 times, and management now expects leverage to finish 2026 below three times.

ENTG Sees Broader Semiconductor Investment CycleManagement raised its 2026 market expectation to 7%-8% growth in million square inches of wafers, up from the mid-single-digit assumption at the start of the year. The outlook reflects stable advanced logic and memory expectations, along with a modestly improving mainstream logic environment.

The company is tracking more than 20 major leading-edge capacity expansions globally, including advanced logic, advanced memory and advanced packaging projects. Bookings strengthened during the quarter, lifting backlog and increasing visibility into customer spending plans through the second half of 2026 and into 2027.

Entegris Initiates Q3 GuidanceFor the third quarter of 2026, Entegris expects sales between $905 million and $935 million. GAAP earnings are projected in the range of 75-83 cents per share, while non-GAAP earnings are forecast between 96 cents and $1.04.

The company expects an adjusted EBITDA margin of 28%-29% and an adjusted operating margin of 24.2%-25.1%. Management also sees fourth-quarter revenues rising about 4% from the midpoint of third-quarter guidance, which would represent mid-teens year-over-year growth.

For 2026, ENTG expects net interest expense of approximately $180 million, a non-GAAP tax rate of about 14% and capital expenditures of $250 million. The share count is projected at roughly 154 million.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in fresh estimates.

The consensus estimate has shifted 11.47% due to these changes.

VGM ScoresAt this time, Entegris has a nice Growth Score of B, a score with the same score on the momentum front. However, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Entegris has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry PlayerEntegris belongs to the Zacks Electronics - Semiconductors industry. Another stock from the same industry, Qualcomm (QCOM - Free Report) , has gained 7.9% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Qualcomm reported revenues of $9.95 billion in the last reported quarter, representing a year-over-year change of -4%. EPS of $2.21 for the same period compares with $2.77 a year ago.

For the current quarter, Qualcomm is expected to post earnings of $2.18 per share, indicating a change of -27.3% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.4% over the last 30 days.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Qualcomm. Also, the stock has a VGM Score of F.

It has been about a month since the last earnings report for International Flavors (IFF - Free Report) . Shares have lost about 1.3% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is International Flavors due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.

International Flavors Q2 Earnings Miss Estimates, Sales Rise Y/YInternational Flavors reported second-quarter 2026 adjusted earnings of 82 cents per share, missing the Zacks Consensus Estimate of $1.14. The company’s second-quarter 2025 adjusted earnings came in at 77 cents, excluding the results from discontinued operations.

Including one-time items, the company reported earnings of 20 cents per share compared with $2.33 in the prior-year quarter.

In late May, International Flavors announced that it inked a deal with CVC Capital Partners to sell its Food Ingredients business. The deal is in sync with International Flavors’ portfolio transformation strategy, which is expected to solidify its focus on its innovation-driven businesses. Starting second-quarter 2026, the Food Ingredients disposal group is reported as discontinued operations.

Net sales rose 1.8% year over year to $1.95 billion but missed the consensus estimate of $2.68 billion. Comparable currency-neutral sales advanced 6%, supported by broad-based growth across Taste, Health & Biosciences, and Scent.

International Flavors’ Q2 Gross Margin Improves Y/YIn the reported quarter, IFF’s cost of goods sold increased 0.5% year over year to $1.10 billion. Gross profit rose 3.5% to $853 million. The gross margin came in at 43.7% compared with 42.9% in the year-ago quarter.

Research and development expenses remained flat year over year at $170 million. Selling and administrative expenses increased 6.8% to $437 million in the second quarter. Adjusted operating EBITDA came in at $408 million, up 2.3% from the prior-year quarter’s $399 million. The adjusted operating EBITDA margin was 20.9% compared with 20.8% in the year-ago quarter.

IFF’s Q2 Segmental PerformancesNet sales in the Taste segment increased 5.2% year over year to $688 million in the June-end quarter. Adjusted operating EBITDA was $124 million, up 6% year over year from $117 million, driven by volume growth and favorable net pricing. The segment’s adjusted operating EBITDA margin was 18% compared with 17.9% in the prior-year quarter.

Sales generated in the Health & Biosciences segment were $601 million, growing 7.5% from the year-earlier quarter’s $559 million. Growth was led by Grain Processing, Food Biosciences and Animal Nutrition. Adjusted operating EBITDA was $150 million in the quarter, up 7.9% year over year from $139 million. The segment’s adjusted operating EBITDA margin was 25% compared with 24.9% a year ago.

The Scent segment’s sales were $665 million, up 10.3% year over year from $603 million. Fine Fragrance posted low-single-digit growth, with results affected by the Middle East conflict Adjusted operating EBITDA increased 10.7% to $134 million from $121 million in the prior-year quarter. The adjusted operating EBITDA margin was 20.2% compared with 20.1% in the year-ago quarter.

International Flavors’ Q2 Cash Flow & Balance Sheet UpdatesIFF had cash and cash equivalents of $569 million at the end of the second quarter of 2026, down from $590 million at the end of 2025. Long-term debt was $4.74 billion at June 30, 2026, largely unchanged from the end of 2025. Net debt to credit-adjusted EBITDA was 2.5X.

International Flavors generated $679 million in cash from operating activities in the first six months of 2026, up from $368 million in the prior-year period.

IFF's 2026 GuidanceFor 2026, International Flavors expects sales from continuing operations of $7.4 billion to $7.6 billion. Adjusted operating EBITDA is projected between $1.53 billion and $1.60 billion. The outlook excludes $3.2 billion in sales and $520 million in adjusted operating EBITDA related to discontinued operations.

The company expects comparable currency-neutral sales growth of 2-4% and comparable currency-neutral adjusted operating EBITDA growth of 4-8%. Foreign exchange is projected to benefit sales growth by 1% and adjusted operating EBITDA growth by 2%.

IFF also authorized an enhanced $2.5-billion share repurchase program, including a planned $500-million accelerated repurchase in the second half of 2026. The remaining $2 billion is expected to be executed after the Food Ingredients divestiture closes, with completion targeted by the end of 2027.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.

The consensus estimate has shifted -20.07% due to these changes.

VGM ScoresAt this time, International Flavors has a subpar Growth Score of D, a score with the same score on the momentum front. Charting a somewhat similar path, the stock has a score of F on the value side, putting it in the bottom 20% quintile for value investors.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise International Flavors has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.

Performance of an Industry PlayerInternational Flavors is part of the Zacks Chemical - Specialty industry. Over the past month, Ashland (ASH - Free Report) , a stock from the same industry, has gained 3.5%. The company reported its results for the quarter ended June 2026 more than a month ago.

Ashland reported revenues of $497 million in the last reported quarter, representing a year-over-year change of +7.3%. EPS of $1.02 for the same period compares with $1.04 a year ago.

Ashland is expected to post earnings of $1.32 per share for the current quarter, representing a year-over-year change of +22.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.6%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Ashland. Also, the stock has a VGM Score of D.

Key Takeaways United Therapeutics' Tyvaso sNDA seeks approval for IPF, with an FDA decision expected in April 2027.TETON studies showed significant FVC gains, reduced clinical worsening and favorable secondary endpoints.Integrated TETON data showed a 111.8 mL FVC benefit, supporting Tyvaso's potential in IPF. United Therapeutics (UTHR - Free Report) recently announced that the FDA has accepted its supplemental new drug application (sNDA) for review, seeking approval for expanded use of its marketed drug, nebulized Tyvaso, in idiopathic pulmonary fibrosis (IPF). A regulatory decision is expected in late April 2027. If approved, the product would be the first FDA-approved inhaled anti-fibrotic treatment for the said indication.

United Therapeutics already markets nebulized Tyvaso for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease. Besides the nebulized formulation, the drug is also approved as a dry powder inhalation (DPI) version for the same indications. The company generates majority of its revenues from the Tyvaso franchise.

IPF is a progressive lung-scarring disease that gradually impairs oxygen transfer, often leading to respiratory failure and death. It primarily affects older adults and may be associated with smoking, genetic factors, environmental exposures and acid reflux. In the United States, at least 100,000 people are estimated to live with IPF, highlighting a significant unmet medical need.

Year to date, shares of United Therapeutics have risen 0.9% compared with the industry’s 0.6% growth.

Image Source: Zacks Investment Research

UTHR’s Tyvaso sNDA for IPF Backed by TETON DataThe sNDA was submitted in June, based on positive top-line data from the TETON program, which consisted of two parallel phase III studies, TETON-1 (conducted in the United States and Canada) and TETON-2 (internationally), designed to evaluate nebulized Tyvaso in patients with IPF. Both studies met their primary endpoints, demonstrating statistically significant improvement in lung function for IPF patients, including a meaningful increase in forced vital capacity (FVC). The studies also reduced the risk of clinical worsening and showed favorable trends across key secondary endpoints.

Integrated analyses of studies reinforced these findings, showing a 111.8 mL FVC benefit and broad secondary endpoint improvements.

In addition to IPF, United Therapeutics is conducting a late-stage TETON PPF study to evaluate the therapy in progressive pulmonary fibrosis (PPF). The company completed patient enrollment in August, with top-line data anticipated in the second half of 2027.

UTHR's Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents per share to earnings of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents per share. PGEN shares have surged 68% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.

Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents per share. ACIU shares have lost 9.6% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Over the past 30 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 71.1% year to date.

Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.